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Abstract
The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up 
in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. With international groups volunteering to join, the 
“APASL ACLF Research Consortium (AARC)” was formed in 2012, which continued to collect prospective ACLF patient 
data. Based on the prospective data analysis of nearly 1400 patients, the AARC consensus was published in 2014. In the past 
nearly four-and-a-half years, the AARC database has been enriched to about 5200 cases by major hepatology centers across 
Asia. The data published during the interim period were carefully analyzed and areas of contention and new developments in 
the field of ACLF were prioritized in a systematic manner. The AARC database was also approached for answering some of 
the issues where published data were limited, such as liver failure grading, its impact on the ‘Golden Therapeutic Window’, 
extrahepatic organ dysfunction and failure, development of sepsis, distinctive features of acute decompensation from ACLF 
and pediatric ACLF and the issues were analyzed. These initiatives concluded in a two-day meeting in October 2018 at New 
Delhi with finalization of the new AARC consensus. Only those statements, which were based on evidence using the Grade 
System and were unanimously recommended, were accepted. Finalized statements were again circulated to all the experts 
and subsequently presented at the AARC investigators meeting at the AASLD in November 2018. The suggestions from the 
experts were used to revise and finalize the consensus. After detailed deliberations and data analysis, the original definition 
of ACLF was found to withstand the test of time and be able to identify a homogenous group of patients presenting with liver 
failure. New management options including the algorithms for the management of coagulation disorders, renal replacement 
Extended author information available on the last page of the article
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therapy, sepsis, variceal bleed, antivirals and criteria for liver transplantation for ACLF patients were proposed. The final 
consensus statements along with the relevant background information and areas requiring future studies are presented here.
Article Highlights
• Updated on the basis of AARC data of >3300 cases enrolled into AARC registry prospectively
• ACLF is distinct form Acute Decompensation of cirrhosis
• Newer sections on DILI-ACLF, AIH-ACLF, PVT/HVOTO–ACLF
• Reversibility of Chronic Liver Disease in ACLF
• Portal and systemic hemodynamics and their relevance in ACLF
• Acute Portal Hypertension and Variceal progression in ACLF
• AARC score as a guide for treatment strategies in ACLF
• ACLF in Children-first consensus on pediatric ACLF
Keywords Liver failure · Cirrhosis · Jaundice · AARC  · Chronic liver disease · Alcoholic liver disease · ALF · 
Decompensation · Acute decompensation
Abbreviations
ACLF  Acute-on-chronic liver failure
DILI  drug-induced liver injury
CAM  Complimentary and alternative 
medicine
HDS  Herbs, drugs and supplements
AD  Acute decompensation
AIH  Auto immune hepatitis
BCS  Budd–Chiari syndrome
PVT  Portal vein thrombosis
AVB  Acute variceal bleed
PICD  Paracentesis induced circulatory 
dysfunction
RRT  Renal replacement therapy
LT  Liver transplant
SOFA  Sequential organ failure assessment
qSOFA  Quick sequential organ failure 
assessment
CANONIC-CLIF  Acute-oN-ChrONic LIver Failure in 
Cirrhosis
CLIF  Chronic Liver Failure Consortium
MELD  Model end-stage liver disease
TPPM  Tongji prognostic predictor model
Introduction
Liver failure is a common medical ailment and its incidence 
is increasing with the use of alcohol and growing epidemic 
of obesity and diabetes. It can present as acute liver failure 
(ALF) (in the absence of any pre-existing liver disease), 
acute-on chronic liver failure (ACLF) (an acute deteriora-
tion of known or unknown chronic liver disease), or an acute 
decompensation of an end-stage liver disease [1, 2]. Each 
of these is a well-defined disease entity with a homogenous 
population of patients with expected outcomes. Due to an 
overlap and lack of clarity of definitions and outcomes, enti-
ties like late-onset liver failure, sub-acute hepatic failure, 
have become less relevant and there is lack of further pub-
lications suggesting removal of such terminologies to avoid 
confusion [1, 2].
The growing interest in ACLF after the first consensus 
definition of ACLF from APASL [2] is evident by the fact 
that more than > 450 publications as full papers have been 
published from the West (2) and the East and the trend is 
increasing. The group of investigators working on liver fail-
ure in the Asia–Pacific region working for the past decade 
carefully analyzed the patient characteristics, natural history 
and outcome of such patients. The group met on yearly basis 
and collated data on website (www.aclf.in). With the setting 
up of the APASL ACLF Research Consortium (AARC) in 
2012, the collaborative research work, publications and pro-
tocol driven unified treatment had gained momentum. The 
retrospective and prospective data of patients from different 
centers were analyzed, and the completed patient records 
were utilized for defining predictors of mortality and grades 
of liver failure and incidence of other organ failures [3].
The APASL ACLF consensus of 2014 was based on 
about 1363 patients from 14 countries. During the past 
nearly four and a half years (2014–2018), 5228 patients of 
43 Centers from 15 countries have so far been registered in 
the AARC database. These patients have been prospectively 
enrolled and followed and form the basis of the new struc-
tured consensus.
Experts from across the world, especially from the 
Asia–Pacific region, were requested to identify pertinent and 
contentious issues in ACLF. After a round of deliberations, 
8 major issues were identified for update. Further, data from 
the AARC database were taken and analyzed and circulated 
to all the participants.
The process for the development of the recommendations 
and guidelines included: review of all available published 
355Hepatology International (2019) 13:353–390 
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literature on ACLF by individual and group of experts; 
preparation of a review manuscript and consensus state-
ments based on GRADE SYSTEM (Table 1) of evidence-
based approach [4], circulation of consensus statements to 
all experts, a survey of the current approaches for the diag-
nosis and management of ACLF; discussion on contentious 
issues; and deliberations to prepare the consensus statement 
by the experts of the working party. A 2-day meeting was 
held on October 1–2, 2018, at New Delhi, India, to discuss 
and finalize the consensus statements, recommendations 
and guidelines. The finalized statements were circulated to 
all the experts and subsequently finalized. These consen-
sus statements and recommendations for the diagnosis and 
management of ACLF are included in this review. A brief 
background is included providing the available data and pub-
lished information on each of the issues. Statements from the 
previous consensus have been reproduced at places to give a 
background and continuity.
The concept of ACLF and hepatic reserve
Acute liver failure is a well-defined medical emergency 
which is defined as a severe liver injury, leading to coagula-
tion abnormality usually with an INR ≥ 1.5, and any degree 
of mental alteration (encephalopathy) in a patient without 
pre-existing liver disease and with an illness of up to 4 weeks 
duration [5].A proportion of patients who present with fea-
tures mimicking ALF, however, have an underlying chronic 
liver disease or cirrhosis of the liver. These patients grouped 
together as acute-on-chronic liver failure (ACLF) also have 
a poor outcome. These patients are distinctly different from 
a group of cirrhotic patients who are already decompensated 
[6] and have a sudden worsening of their condition, i.e., 
acute decompensation (AD) due to an acute event that may 
present with hepatic or non-hepatic failure [6].
ACLF is a clinical syndrome manifesting as acute and 
severe hepatic derangements resulting from varied insults. 
This term was first used in 1995 to describe a condition in 
which two insults to liver operate simultaneously, one of 
them being ongoing and chronic and the other acute [7]. 
Over the years, several definitions have been proposed, cre-
ating confusion in the field [8]. The time frame for the devel-
opment of liver failure and ACLF has been several times 
changed from 12 to 4 weeks again to 12 weeks [9]. Moreo-
ver, the nature of insult and the stage of underlying disease 
have been variably used.
In fact, any patient who has an underlying chronic liver 
disease with superimposed acute insult is labeled as hav-
ing ACLF, irrespective of evidence of liver failure per se or 
evidence of pre-existing cirrhotic decompensation. Several 
investigators were concerned that this would lead to sub-
stantial overlap with decompensated liver disease. The main 
emphasis of the fourth consensus meeting of the APASL 
Working Party was to identify from this large group of 
patients, a subset of patients who have a relatively homog-
enous presentation and potentially similar outcome and 
restrict the use of the term ‘‘acute-on-chronic liver failure’’ 
to this subset. The 2009 APASL definition had provided a 
basis to select patients presenting with a distinct syndrome. 
To cover the entire spectrum of these patients, from mild 
to most severe, patients with chronic liver disease with or 
without cirrhosis of the liver were included and carefully 
analyzed. It is understandable, though not well defined, that 
the nature and degree of acute insult and the status of the 
underlying chronic liver disease would determine the out-
come in a patient (Fig. 1).
To give clarity to the primary event, a hepatic insult, 
jaundice and coagulopathy, which defined liver failure, was 
considered essential. In acute liver failure, though hepatic 
encephalopathy (HE) is part of the definition, it follows liver 
failure. Should one wait for defining the outcome of ‘acute 
liver failure’ till the time extrahepatic organ failures set in or 
not, remains contentious. For definition, the event must be 
universally present in all patients. From the point of view of 
intensivists, it is well known that with increasing number of 
organ dysfunction or failure, the mortality would cumula-
tively increase. Undoubtedly, these events are predictive of 
the outcome, the basis of SOFA score [10]. It is, therefore, 
Table 1  Evidence grade used for the APASL Guidelines Adopted from Atkins et al. [4]
Grading of evidence Notes Symbol
High quality Further research is very unlikely to change our confidence in the estimate effect A
Moderate quality Further research is likely to have an important impact on our confidence in the estimate of effect 
and may change the estimate effect
B
Low or very low quality Further research is very likely to have an important impact on our confidence in the estimate of 
effect and may change the estimate effect. Any estimate of effect is uncertain
C
Grading of recommendations Notes Symbol
Strong recommendation warranted Factors influencing the strength of the recommendation included the quality of the evidence, 
presumed patient-important outcomes, and cost
1
Weaker recommendation Variability in preferences and values, or more uncertainty: more likely a weak recommendation is 
warranted. Recommendation is made with less certainty: higher cost or resource consumption
2
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not surprising; the same has been reported in the Western 
studies [11]. However, should organ failure be included in 
defining the clinical syndrome of liver failure needs a thor-
ough analysis. As a corollary, despite decades of extensive 
experience, renal or circulatory dysfunction has not been 
included in the definition of ALF. The issue whether sepsis 
per se could lead to liver failure or is a result of liver failure 
had been debated for many years and was again revisited. 
However, sepsis is an integral part of development of multi-
organ failure in any patient, be it of renal, pancreatic or car-
diac origin.
In essence, ACLF is a distinct entity where acute hepatic 
decompensation occurs in an established chronic liver dis-
ease or cirrhosis patient on exposure to acute insult in a 
defined time frame resulting in a high short-term mortality. 
Based on the data, attempts were made if the current defi-
nition of ACLF could be improved further (Table 2). Five 
aspects were worked upon:
(1) The time frame for the acute insult in the initial (2009) 
and subsequent definition of ACLF, the time for devel-
opment of ascites and/HE after appearance of jaundice 
and coagulopathy was kept as 4 weeks (28 days) [1, 2]. 
A mortality rate of more than 33% at 4 weeks was con-
sidered to be significant allowing recovery to less than 
two-third of the patients in the 2014 consensus. The 
additional new data after the previous consensus were 
carefully analyzed and it showed a 4-week mortality of 
around 39.9% [2]. Therefore, the definition of 4 week 
for acute insult in ACLF was considered as appropriate 
and was maintained.
2. Reversibility of the ACLF syndrome this is a feature of 
the ACLF defined by the AARC criteria, as nearly all the 
patients included are after the index presentation. With 
mitigation of acute insult and over time, the hepatic 
reserve improves, fibrosis regresses and the portal pres-
sure decreases. It was decided to define reversibility as 
reversal of key components that were used for defining 
the syndrome of liver failure, i.e., decrease of bilirubin 
below 5 mg/dL and reversal of coagulopathy to INR 
below 1.5 and no encephalopathy with or without reso-
lution of ascites. It was interesting to find in the large 
AARC database, of the 1844 patients with complete data 
until day 90. About 70% of the survivors beyond day 90, 
showed reversibility and they maintained this status for 
a period of at least 1 year. Further, unlike patients with 
decompensated cirrhosis and similar to patients with 
ALF, the reversal of coagulopathy preceded the reversal 
of jaundice, i.e., median time to reversal of coagulopathy 
was 7 (4–30) days versus 19 (7–60) days for jaundice, 
respectively. The median time to reversal of syndrome, 
i.e., jaundice and coagulopathy, was 30 days. Baseline 
albumin, AARC score and transient elastography pre-
dicted long-term reversibility in the recently analyzed 
AARC data.
3. Recording ‘Index ‘or first presentation in the definition 
of ACLF this issue was deliberated so as to define and 
include a homogenous cohort of patients. The considera-
tion of prior decompensation with recent worsening (dif-
ficult to differentiate from acute decompensation, AD) 
or recovery from ACLF and followed by subsequent 
presentation as ACLF (i.e., ‘ACLF again’) will lead to 
confusion. It is important to distinguish the syndrome 
of ACLF from other forms of liver failure, such as acute 
decompensation and end-stage liver disease (ESLD). 
There was a consensus to initiate prospective studies 
comparing patient manifesting with index presentation, 
prior decompensation or recent worsening of decompen-
sated cirrhosis patients.
Fig. 1  Concept of ACLF and 
the cohorts included in different 
definitions. The figure describes 
the response of the liver to an 
acute hepatic injury, depend-
ing on the underlying hepatic 
injury, prior decompensation, 
time frame from insult to pres-
entation with decompensation 
and reversibility with mitigation 
of the acute insult. The spec-
trum extends from acute liver 
failure, acute-on-chronic liver 
failure, acute decompensation, 
end-stage liver disease. ACLF 
is distinct like ALF when the 
APASL definition is considered. 
APASL definition is simple and 
homogenous and is distinct
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4. Inclusion of mortality in definition the mortality was 
included in 2014 AARC consensus definition for iden-
tifying a set of patients who have high 28-day mortality 
so as to prioritize them for admission, treatment and 
liver transplantation. At present, the ACLF definition 
both by the APASL and CLIF-EASL includes mortality. 
The group of experts raised the concern that mortality 
is generally not part of definition in disease conditions. 
Other experts, however, disagreed to this. After due 
deliberations, it was decided to keep the statement on 
mortality, in the AARC-ACLF definition.
5. Inclusion of organ failure in definition the Western defi-
nitions of ACLF include organ failure in the definition. 
This issue was debated extensively. The data from the 
AARC database were also analyzed. It was reiterated 
that organ failure other than liver should not be part 
of the definition. Diagnosis of liver failure along with 
kidney, circulatory and respiratory failure is generally 
a late event and is often a result of the primary organ, 
i.e., liver failure (jaundice, deranged coagulation and/or 
HE). The experts felt that organ dysfunction rather than 
organ failure should be the time for raising suspicion 
and making diagnosis of ALCF rather than when organ 
failure(s) has already developed. This approach would 
help in prioritizing organ-specific interventions.
The AARC definition of ACLF is a simple bed-side tool 
(requires history taking, physical examination and simple 
laboratory parameters) and can be used by primary care giv-
ers. It enables a clinician to stratify a patient presenting with 
liver failure for early referral, early intervention and, hence, 
allows a better chance of reversibility as well as improved 
survival. The earlier criteria for defining the nature of acute 
insult were reiterated, i.e., the event must be new and acute 
and its impact on the patient’s condition should be discern-
ible as liver failure within a given time frame of 4 weeks 
[1, 2].
Recommendations
 1.0  The concept of ACLF and hepatic reserve.
 1.1   The 28- and 90-day mortality is high in ACLF 
patients (A1).
 1.2.   Among the survivors at day 90, the reversal of 
ACLF syndrome was noted in nearly 70% cases 
(C2).
 1.3.   Almost two-third of the patients, who had reversal 
of the ACLF syndrome by day 90, show a persistent 
regression of the disease at 1 year (C2).
 1.4.   Reversal of coagulopathy precedes the reversal of 
jaundice (C2).
 1.5.   The baseline AARC liver failure grade can identify 
patients who are likely to reverse (C2).
 1.6.   A higher platelet count, lower leukocyte count and 
the absence of HE are additional independent pre-
dictors of reversibility (C2).
 1.7.   Transient elastography needs to be evaluated for 
identifying the reversibility of ACLF syndrome at 
baseline as well as at follow-up (C2).
 1.8   Will inclusion of terminology of ‘First’ presentation 
in definition improve clarity and homogeneity.
 1.8.1.  Inclusion or exclusion of prior decompensation and 
‘first’ presentation for the definition of ACLF needs 
prospective studies [B2].
 1.9.   Including organ failure in definition- for utility or 
futility?
 1.9.1.  The terms “organ dysfunction” and “organ failure” 
need to be described more clearly based on the 
AARC database, used in APASL consensus [B2].
 1.9.2.  Extrahepatic organ failure should not be included 
in definition of ACLF, as this would lead to missing 
out the potential therapeutic window for reversal of 
the ACLF syndrome (A1).
 1.9.3.  Liver failure for definition of ACLF should include 
jaundice (serum bilirubin ≥ 5 mg/dL) and coagula-
tion dysfunction (INR > 1.5) (A1).
 1.10.  Whether mortality should be part of definition?
 1.10.1.  Mortality should not be part of the definition of 
ACLF. One need not die to fulfill the criteria of 
ACLF definition. Mortality is not generally part of 
any definition in disease conditions (C2). However, 
since the earlier (2014) definition had included 
mortality, the same definition was agreed.
Definition of ACLF
There is no consistent definition of ACLF in the literature. 
Each study done previously on ACLF has used its own 
definition, and there is no unanimity in these definitions in 
terms of criteria for liver failure, the acute event precipi-
tating ACLF, and the diagnosis of underlying chronic liver 
disease. Since most of these studies were on patients who 
required liver support devices or liver transplantation, these 
studies were biased toward including sicker patients in the 
definition and patients having a mild disease were left out.
A detailed analysis of the definition of liver failure and 
the need for the defined outcome of high 28-day mortal-
ity was taken into account. An estimated 33% mortality 
at 28  days was considered important. Having analyzed 
and defined the acute and chronic insults, the time frame 
and the criteria of liver failure, development and course of 
organ failure and sepsis, the APASL definition of ACLF 
of 2009 was reassessed. It was reported that this definition 
has been used in nearly 200 publications from the East and 
the West and has been found to be simple to use and with a 
high degree of predictive ability to define the outcome of a 
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relatively homogenous group of liver failure patients with 
underlying chronic liver disease.
The consensus definition is:
“ACLF is an acute hepatic insult manifesting as jaun-
dice (serum bilirubin ≥ 5 mg/dL (85 micromol/L) and 
coagulopathy (INR ≥ 1.5 or prothrombin activity < 40%) 
complicated within 4 weeks by clinical ascites and/or 
encephalopathy in a patient with previously diagnosed or 
undiagnosed chronic liver disease/cirrhosis, and is associ-
ated with a high 28-day mortality.” (I, A).
Defining the acute insult
The spectrum of acute insult in the Asian region was revis-
ited, while hepatitis B reactivation remains the predominant 
cause of acute hepatic insult in the East, from the global 
perspective. The trends showed an increase in the proportion 
of alcoholic hepatitis over the years. This was a bit unex-
pected for the Asian countries where alcoholic hepatitis is 
emerging as a major acute insult and shows the growing 
westernization of Asia. A review of the recent CANONIC 
study data showed that in the West the term precipitating 
event is generally used and probably details of events such 
as Hepatitis B or superadded hepatitis A and E are rarely 
encountered or recorded [11]. Surprisingly, even the active 
alcohol abuse and alcoholic hepatitis were also not the pre-
dominant causes. A plausible explanation could be that since 
the CANONIC study only recorded the acute decompensa-
tion of cirrhosis and not the hepatic insults, the major events 
recorded were only non-hepatic, such as bacterial infections 
or sepsis. Acute decompensation of cirrhosis is a different 
entity than ACLF. As the core premise of ACLF is presen-
tation as liver failure, the acute insults should be hepatic 
insults. Both hepatotropic and non-hepatotropic insults 
should manifest in the patient first with liver failure.
Acute hepatic insults of infectious etiology included reac-
tivation of hepatitis B virus (HBV) as the leading cause of 
ACLF in the Asian region [12–20]. Reactivation of HBV 
could be either spontaneous or due to intensive chemother-
apy or immunosuppressive therapy [12, 13], immune resto-
ration after highly active antiretroviral therapy for HIV [14, 
15], treatment related [16], or reactivation of the occult HBV 
infection by rituximab (anti-CD20)-based chemotherapy 
[17–19]. Similarly, reactivation of hepatitis C virus infection 
has also been reported, especially after immune suppressive 
therapy [20, 21]. The other very important infectious etiol-
ogy of the acute event is super-infection with hepatitis E 
virus, predominantly in patients in the Indian subcontinent 
[22–25]. Various bacterial, parasitic, and fungal infections 
may affect the liver. Spirochetal, protozoal, helminthic, 
or fungal organisms may directly infect the liver, whereas 
bacterial or parasitic infection may spread to the liver from 
other sites [26]. These infections may lead to liver failure 
in patients with underlying chronic liver disease. Among 
the non-infectious etiologies, alcoholic hepatitis is the major 
cause of acute deterioration in stable known or unknown 
chronic liver diseases, more often in the western countries 
[27, 28]. It was not clear what should be the interval from 
the last alcoholic drink to be included as acute insult. Since, 
after the direct hepatic injury, the immunological injury 
starts to decline [29], a period of 28-day was considered 
adequate for inclusion as the last drink. The issue, which 
remained to be addressed, was of binge drinking in patients 
with ACLF due to recent alcohol intake. It was appreciated 
that a prospective data collection including the drinking 
behavior especially in the past 6 months would help decide 
the influence of drinking behavior on the clinical outcome 
and help in defining the time frame of what should be con-
sidered as an acute insult (Fig. 2).
(A) Drug-induced liver injury (DILI) presenting as 
ACLF is an important entity less often addressed in the 
Global literature. Hepatotoxic drugs and complementary 
and alternative medicines (CAM) are important causes for 
acute and acute-on-chronic liver failure in the Asia–Pacific 
region [30]. While most drugs are safely tolerated in the 
setting of CLD, recent work suggests that individuals with 
CLD may be at increased risk to develop hepatotoxicity at 
least to certain drugs [31]. Hepatitis following the use of 
anti-tubercular drugs was considered to be an important 
cause of acute insult leading to ACLF. In a proportion 
of patients, despite a history of use of CAM, the precise 
nature and injurious influence of the agent cannot be 
determined. Results from the drug-induced liver injury 
network have demonstrated that mortality in 89 patients 
with pre-existing liver disease was 16% which was sig-
nificantly higher than the 5% mortality in 810 patients 
with underlying liver disease [32]. Drugs such as anti-
tuberculosis drugs, methotrexate and antiretroviral drugs 
in HIV/AIDS-infected individuals have been implicated 
as triggering liver injury include particularly in the setting 
of underlying chronic liver disease due to hepatitis B or 
C [33–37]. Paradoxically CLD or cirrhosis is a risk factor 
for tuberculosis [38, 39] and first-line anti-tuberculosis 
drugs have been consistently shown to increase the risk of 
hepatotoxicity, particularly in hepatitis B and C [40, 41]. 
Although drugs have been listed as a precipitant factor 
in ACLF, data are scarce except from the APASL/AARC 
database. Data from the West is lacking on drugs as an 
acute insult leading to ACLF. In Asia 1.8% [42] to 5.7% 
[43, 44] precipitating events for ACLF are related to drugs. 
In Chinese cohort, the drugs were mostly from herbal or 
traditional medications to anti tuberculosis drugs in Indian 
cohorts [44]. From the AARC database, 329 (10%) of the 
3132 patients of ACLF had an inciting event due to drugs. 
There is, however, need for further data and work on the 
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modes of hepatic injury caused by different herbal and 
medicinal preparations on patients with cirrhosis.
(B) Autoimmune hepatitis flare leading to ACLF has not 
been adequately addressed in both Asia Pacific as well as 
Western cohorts. The pattern of clinical presentation spans 
from benign chronic hepatitis and indolent disease to acute 
liver failure. The abrupt presentation can indicate spontane-
ous exacerbation of a pre-existent chronic disease (present-
ing as ACLF), newly developed disease (presenting as ALF), 
a superimposed infectious or toxic injury, or new disease 
after viral infection, drug therapy, or liver transplantation. 
Approximately, 20% of patients with autoimmune hepatitis 
present with severe jaundice, HE and coagulopathy, with or 
without ascites, which resemble ALF or ACLF [45]. The 
disease usually has an unusual presentation with nearly half 
the patients being seronegative, requiring a lower threshold 
for transjugular liver biopsy. The histological features are 
distinct from those found in fulminant AIH. Stravitz et al. 
[46] identified lymphoid aggregates, perivenulitis and mas-
sive hepatitic necrosis as suggestive histological features 
of AIH–ALF [47]. The multicentric AIH-ACLF data from 
AARC database, which showed that the lymphoid aggregates 
and perivenulitis are less common in AIH-ACLF. However, 
advanced fibrosis (F3/F4), ductular reactions, and large areas 
of parenchymal collapse with lymphoplasmacytic inflamma-
tion are prominent findings along with classical autoimmune 
features in AIH-ACLF. It was observed that use of steroid 
in a select group of moderately severe AIH has a favorable 
outcome. Autoimmune hepatitis (AIH) was the first liver 
disease for which an effective therapeutic intervention was 
provided and treatment efficacy shown [47].
(C) Acute variceal bleeding has been included as one of 
the events to define acute decompensation in the natural 
history of cirrhosis [48]. Variceal bleeding has also been 
taken as an acute insult for ACLF in some western trials of 
ACLF. A scenario may exist that a patient who has already 
fulfilled the criteria of ACLF and has been diagnosed 
ACLF, develops a variceal bleed. In such a patient, variceal 
bleed would be considered as a complication in the natural 
history of ACLF. In recently analyzed 1028 compensated 
cirrhosis patients presenting with acute variceal bleed, the 
syndrome of ACLF was seen in 4% cases. Acute variceal 
bleed led to 10% mortality in compensated cirrhosis, which 
increased to 18% in 90-day follow-up with the development 
of ACLF (p < 0.001). A large set of data was mined and the 
issue was debated whether to consider variceal bleed as 
an acute event of ACLF. However, since the definition of 
ACLF includes liver failure, jaundice and coagulopathy, the 
variceal bleed should result in liver failure. The liver failure 
in such patients is likely to be due to hepatic ischemia [49] 
and subsequent bacterial infections [50]. It was discussed 
that for a patient with portal hypertension and cirrhosis 
of the liver who presents for the first time with variceal 
bleed without any previous or present signs or symptoms of 
Fig. 2  Sequence of events in Diagnostic Criteria of ACLF: East vs. 
West. The figure clearly describes the sequence of organ failure and 
its mechanism. An acute hepatic insult leading to hepatic decompen-
sation is the driver and subsequent extrahepatic organ failure is due 
to failure of recovery/regeneration and development of sepsis after a 
Golden Window. With consideration of sepsis as the intiating factor 
and development of extrahepatic organ involvement as a part of defi-
nition leads to late identification of the ACLF patients where the ther-
apeutic windos is lost. The difference between ACLF, AD and ESLD 
(as in Fig. 1) is blurred and entity is heterogenous. So pure hepatic 
insult leading to hepatic failure at the beginning and subsequent 
extrahepatic organ failure as complication, not defining complex is 
the crux in managing this group of liver disease patient
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chronic liver disease, it would not constitute an acute insult. 
This is especially relevant if such a patient does not develop 
any jaundice. The experts discussed the stratification of 
patients based on the stage of underlying liver disease and 
the severity of variceal bleed. Based on the data, it was 
unanimously agreed that acute variceal bleeding is not an 
acute hepatic insult unless in the patients where it produces 
jaundice and coagulopathy fulfilling the criteria of ACLF.
(D) Acute HVOTO or PVT presenting as ACLF is a novel 
concept. The disease burden, clinical picture, prognosis and 
treatment strategies of BCS or PVT presenting as ACLF 
are largely unknown. The thrombophilic disorders in those 
with ACLF have not been evaluated but are unlikely to be 
different from those without ACLF. The reduction of hepatic 
blood flow due to acute PVT may lead to ischemic liver 
injury [51]. The diagnosis of acute-on-chronic BCS in the 
study by Langlet et al. was based on the presence of both 
acute and chronic features, clinically and/or radiologically 
[52]. However, the entity of ACLF was not described at that 
time and it is unclear if any of these patients would have 
fulfilled the criteria of ACLF. However, it was reported 
that these patients had worse outcome as compared to other 
patients with Budd–Chiari syndrome. Evaluation of throm-
bophilic disorders in patients with PVT or BCS and ACLF 
should be similar to those without ACLF. There is no evi-
dence currently to suggest that non-cirrhotic portal fibrosis 
or EHPVO may present as ACLF.
The issue of other non-hepatotropic insults which have 
been considered in other studies such as surgery, trauma, 
insertion of transjugular intrahepatic portosystemic shunt, 
trans-arterial chemoembolization or radiofrequency ablation 
for hepatocellular carcinoma was discussed in detail. While 
there is an indirect connection with each of these, it was 
debated that a patient who already has cirrhosis with HCC 
or a cirrhotic who undergoes surgery, separate risk scores are 
already in practice and being utilized. The likely potential 
for hepatic decompensation would vary depending on the 
nature of intervention and underlying hepatic reserve. It was 
agreed that non-hepatotropic insults producing direct hepatic 
insult and ACLF in an otherwise compensated liver disease 
could be considered as acute hepatic insults. In a proportion 
of patients in Asia or even in the west, the precise agent(s) 
leading to acute hepatic insult are not well recognized on 
routine assessment. In such patients, this should be recorded 
as such.
Recommendations
 2.1.  Defining the acute event in ACLF.
 2.1.1. Infections.
 2.1.1. Hepatotropic infections.
 2.1.1.1.  Hepatotropic viral infections: In this group, reac-
tivation of Hepatitis B virus (HBV) infection 
and super-infection with hepatitis virus are the 
major causes of acute insults for precipitating 
ACLF (1, A).
 2.1.1.2  Hepatotropic non-viral infections: These include 
bacterial, parasitic, and fungal infections precipi-
tating liver failure and ACLF (2, C).
 2.1.2.  Non-hepatotropic infections.
 2.1.2.1.  Bacterial infection is unlikely to be the precipitant 
in individuals with a definite hepatotropic acute 
insult (2, B).
 2.1.2.2.  Bacterial infections, if they primarily precipitate 
hepatic failure, and present as ACLF, may be con-
sidered as a precipitant of ACLF, but data at present 
are inadequate to demonstrate that infection per se 
could lead to jaundice and liver failure (2, C). Drug-
induced liver injury (Drugs, CAM & HDS)—with 
or without cirrhosis.
 2.1.2.1.  Drug-induced ACLF (ACLF-D) is a distinct entity 
than DILI [1, A].
 2.1.2.2.  Diagnosis of ACLF-D is challenging as liver dis-
ease-related fluctuations in the liver function tests 
may be part of the natural history of the disease 
and may confound the diagnosis. Further, cirrhotic 
patients may not show marked derangements in 
transaminases [1, B].
 2.1.2.3.  Those who develop ACLF-D are likely to have 
severe consequences including decompensation 
and death (1, B).
 2.1.2.4.  Drugs responsible as acute insults, trigger-
ing ACLF-D in cirrhosis patients include anti-
tubercular drugs, Complimentary and alternative 
medications, antiretroviral drugs and Methotrex-
ate (1, B). More evidence is needed for drugs like 
azithromycin, azole antifungals and antimicrobi-
als in cirrhotics (2, B).
 2.1.2.5.  Risk of liver injury is proportional to the number 
of hepatotoxic drugs in anti-TB regimen (2, C).
 2.1.3.  Autoimmune liver disease—distinction in presenta-
tion as ACLF and ALF.
 2.1.3.1.  ACLF-AIH frequently presents as seronegative for 
autoantibodies or normal IgG levels [B2]. Seron-
egative AIH cases might be overlooked without 
histology [1, B].
 2.1.3.2.  Diagnosis of ACLF-AIH requires liver biopsy (tran-
sjugular route preferred). Biopsy is more helpful in 
patients where etiology is not evident; antibodies 
and IgG are negative but there is a high index of 
suspicion (like extrahepatic features of autoimmun-
ity/family history of autoimmunity or autoimmune 
diseases like vitiligo, thyroiditis) [1, B].
 2.1.3.3.  Frequency/degree of fibrosis may define chronicity 
(ACLF or ALF), but fibrosis may progress in a few 
weeks from F0 to F1–2 [2, C].
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 2.1.3.4.  Corticosteroid therapy should be considered for a 
select group of patients presenting with ACLF-AIH 
[2, B].
 2.1.4.  Acute variceal bleed.
 2.1.4.1.  The frequency of acute variceal bleed (AVB) 
increases with severity of cirrhosis [2, B}.
 2.1.4.2.  AVB in compensated cirrhosis (Child A) leads to 
the development of ACLF in less than 5% cases 
[2, B].
 2.1.4.3.  Mortality in compensated cirrhosis increases with 
the development of ACLF in 90 day follow-up post-
variceal bleed [2, B].
 2.1.4.4.  Incidence of post-EVL ulcers in ACLF is higher 
than that in cirrhosis [1, C].
 2.1.4.5.  Though infrequent, AVB can lead to ACLF in small 
proportion of Child A patients. Further studies are 
required in patients with Child B [2, C].
 2.1.5.  Vascular liver diseases (PVT, HVOTO).
 2.1.5.1.  In patients with cirrhosis, development of acute 
occlusive portal vein thrombosis (PVT) may pre-
cipitate ACLF in a small sub-group (2, C).
 2.1.5.2.  In patients with cirrhosis or Budd–Chiari syn-
drome, development of acute hepatic vein throm-
bosis (PVT) may precipitate ACLF (2, C).
 2.1.5.3.  Patients with Budd–Chiari syndrome (BCS) may 
infrequently present with or develop ACLF (2, C).
 2.1.5.4.  Evaluation of thrombophilic disorders in patients 
with PVT or BCS and ACLF should be similar to 
those without ACLF (2, C).
 2.1.5.5.  There is no evidence currently to suggest that non-
cirrhotic portal fibrosis or EHPVO may present as 
ACLF (2, C).
 2.1.5.6.  No data are available about the natural history or 
outcome of patients with PVT or BCS presenting 
with ACLF and no recommendations can be made 
for management of patients with vascular liver dis-
eases and ACLF (2, C).
Defining the underlying chronic liver disease
Two aspects were carefully analyzed, what constitutes 
chronic liver disease, cirrhosis alone or non-cirrhotic chronic 
liver diseases and the etiology of the chronic liver disease.
The degree of hepatic fibrosis and the functional hepatocel-
lular mass remains heterogeneous in patients with the chronic 
hepatitis [53, 54]. Even in patients with stage IV fibrosis, criti-
cal mass varies according to the parenchymal reserves. Modi-
fied Laennec Scoring System divides stage IV further, accord-
ing to the thickness of septa into three, ending up in six stages 
altogether [55, 56]. Moreover, ACLF is not equivalent to the 
acute decompensation of cirrhosis, which has protean mani-
festations. Majority of the ACLF patients present with liver 
failure without any previous assessment of liver disease. It is not 
possible to distinguish accurately the natural history of patients 
with different degree of fibrosis presenting with ACLF at this 
point in time. The liver with any significant degree of fibrosis, 
with activated stellate cells, and infiltrated by the inflammatory 
cells, is expected to respond in a different way to the acute insult 
compared to the liver without inflammatory infiltrate [57].
NAFLD is the leading cause of donor rejection in liver 
transplantation [58]. Experience from liver transplantation 
centers shows that steatosis greater than 30% in the donor 
liver is associated with a higher risk of primary non-function 
and graft initial poor function as compared to grafts with no 
or less than 30% steatosis [59]. Patients with metabolic syn-
drome and fatty liver, diabetics, male patients of age greater 
than 45–50 years, and patients with obesity and dyslipidemia 
have increased risk of fibrosis [60]. While cirrhosis could be a 
late event, a large proportion of patients may have stage 2 or 3 
fibrosis. Hence, NASH is indeed an important cause of chronic 
liver disease [61]. Furthermore, in the East, a large proportion 
of patients do have reactivation of chronic hepatitis B. In these 
patients, while liver failure and ACLF-like presentation do 
develop, cirrhosis is not necessarily present. The AARC data 
based on the liver biopsy studies corroborated the facts that a 
fair proportion of patients with ACLF do not have full-fledged 
cirrhosis, but still carry a poor prognosis, with mortality above 
33% at 4 weeks. Based on the current data set, and published 
literature and the validity of the 2009 consensus on including 
the non-cirrhotic chronic liver disease were reaffirmed.
Accurate and reliable assessment of underlying CLD in 
the setting of ACLF is important for the subsequent manage-
ment and need for liver transplant in these patients. Diagno-
sis of chronic liver disease in the setting of ACLF is made 
by history, physical examination, and previously available 
or recent laboratory, endoscopic or radiological investiga-
tions [62]. Ultrasound and CT abdomen may pick up CLD. 
However, to assess the degree of fibrosis in an un-shrunken 
liver would require other radiological modalities. The cur-
rent non-invasive tests cannot clearly diagnose the presence 
of chronic liver disease in the presence of inflammation and 
liver failure. Hence, liver biopsy through the transjugular 
route or occasionally through laparoscopy remains an impor-
tant tool to confirm the stage of fibrosis and presence of 
cirrhotic or non-cirrhotic liver disease.
A liver biopsy through the transjugular route may be of 
help when the presence of already underlying CLD and the 
cause of liver disease are not clear. The liver biopsy may 
highlight the etiology, stage of fibrosis, prognosis and out-
come in patients with ACLF [63]. In addition, transjugu-
lar access directly into the hepatic vein allows the hepatic 
venous pressure gradient to be measured (HVPG). There is 
a risk of bleeding leading to hemobilia, hemoperitoneum, 
and hepatic hematoma in the setting of the deranged clot-
ting profile [64]. The need of liver biopsy in ACLF should, 
therefore, be individualized. Standardization of liver biopsy 
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assessment would help a uniform approach to the diagnosis 
and treatment of CLD and the acute insult.
There is a need to have reliable non-invasive tools to 
assess the severity of fibrosis in a previously undiagnosed 
CLD. Ultrasound and CT abdomen may pick up CLD. How-
ever, to assess the degree of fibrosis in an unshrunken liver 
would require other radiological modalities. Transient elas-
tography is a good modality to detect hepatic fibrosis [65]. 
However, the liver tissue stiffness may also increase with 
hepatitis, steatosis, and inflammation present in the ACLF 
setting [66].
The second issue was about the etiology of chronic liver 
disease and cirrhosis in the Asian pacific region. The experts 
reviewed the data from the AARC database and the etiologic 
profile of cirrhosis in ACLF was found to be similar to etiol-
ogy of cirrhosis in general in the respective countries [28, 
67, 68]. With the rising incidence of obesity and NAFLD, 
a proportion of burnt-out NASH presenting as cryptogenic 
cirrhosis also increases [69–71]. Viral serology and nucleic 
acid testing are required to identify viral etiology. Special-
ized tests to diagnose metabolic and autoimmune diseases 
are needed as well. The presence of stigmata of liver disease 
on clinical examination, low platelets, evidence of synthetic 
dysfunction in previous reports, and altered AST/ALT ratio 
in previous reports should prompt the diagnosis of the pres-
ence of CLD [72, 73].
Recommendations
 2.2.  Defining the underlying CLD:
 2.2.1.  Cirrhotic and non-cirrhotic chronic liver diseases 
qualify as chronic liver diseases (1, A).
 2.2.2.  The common underlying chronic liver diseases 
include alcohol, hepatitis B, hepatitis C, NAFLD-
related chronic liver disease or cirrhosis of the liver 
(1, A).
 2.2.3.  Chronic hepatitis and/or significant fibrosis without 
cirrhosis should be taken as a chronic liver disease, 
if such a patient presents as ACLF (1, B).
 2.2.4.  NAFLD-related chronic hepatic injury; NASH, if 
associated with significant fibrosis, should be taken 
as a chronic liver disease in ACLF (1, B).
 2.2.5.  Patients with known previous decompensation with 
jaundice, HE, and ascites should be excluded (1, C).
 2.2.6.  Diagnosis of chronic liver disease and cirrhosis in 
the setting of ACLF is made by history, physical 
examination, laboratory, endoscopic or radiological 
investigations (1, A).
 2.2.7.  A liver biopsy through the transjugular route may 
be helpful when the presence of underlying chronic 
liver disease and/or the cause of chronic liver dis-
ease and/or the acute insult is not clear (1, B).
Impact of comorbidities and obesity
Comorbidities also influence the outcome of ACLF as far as 
the disease and outcome are concerned. The presence of co-
morbidities like obesity, sarcopenia and other metabolic risk 
factors like diabetes mellitus, hypertension and dyslipidemia 
have a bearing on the outcome of patients with cirrhosis 
[74]. However, there is a sparse literature on the effect of 
obesity, sarcopenia and other metabolic risk factors on the 
severity and outcome of patients with acute-on-chronic liver 
failure (ACLF). In a recent analysis of the AARC database, 
the prevalence of metabolic risk factors and its impact on the 
severity and outcome were analyzed in patients with alcohol-
related ACLF as per the APASL definition [75]. In a recent 
report, of the 1028 patients from AARC database, 15% 
patients had history of overweight or obesity, 14% of T2DM, 
7% of HT and 15% of dyslipidemia. Patients with metabolic 
traits compared with control group, had more severe disease; 
those with overweight or obesity had significantly higher 
MELD score and those with dyslipidemia had higher AARC 
score. None of the other metabolic risk factors either alone 
or in combination had any impact on the severity of ACLF. 
The presence of overweight or obesity was also significantly 
associated with increased day 30 mortality while none of the 
other metabolic risk factors, alone or in combination were 
associated with day 30 or 90 mortality [75]. In addition to 
above, alcohol intake and subsequent chronic liver disease 
with or without cirrhosis is another co-morbid condition.
Recommendations
 2.3.  Impact of comorbidities and obesity.
 2.3.1.  The presence of overweight or obesity and dys-
lipidemia increases the severity of liver disease in 
ACLF patients (1, B).
 2.3.2.  The presence of overweight or obesity increases 
the short-term (30 day) mortality in patients with 
ACLF (1, B).
 2.3.3.  There is need to compare the development and 
natural history of ACLF in patients with NASH 
versus NASH cirrhosis (2, C).
Changing trends for the etiology of acute insult and chronic 
injury
The epidemiology of acute insult has changed signifi-
cantly in the past 5 years. In the recent AARC data, alcohol 
has now emerged as the most common etiology for acute 
insult (49%) as well as for underlying chronic liver disease 
in contrast to previuos data of HBV predominance. DILI 
and autoimmune etiologies have shown increasing trend; 
however, HAV/HEV had decreasing trend. HBV infection-
induced ACLF as well as HAV/HEV-induced ACLF is now 
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showing a decreasing trend over time, whereas alcohol and 
herbs, drugs and supplements (HDS)-induced ACLF show 
an increasing trend. The unknown causes for acute insult and 
chronic injury constitute only 5–15% cases of ACLF in the 
East in contrast to the West, where these are seen in about 
40% of ACLF patients.
Recommendations
 2.4.   Changing trends for the etiology of acute insult 
and chronic injury.
 2.4.1.  Alcohol is now the commonest etiology for acute 
hepatic insult as well as for the underlying chronic 
liver disease in the Asian continent [2, B].
 2.4.2.  DILI and autoimmune etiologies have shown 
increasing trend [2, B].
 2.4.3.  HBV infection–reactivation of hepatitis B-induced 
ACLF as well as acute HAV/HEV-induced ACLF 
shows a decreasing trend over time in certain 
regions, whereas alcohol and herbs, drugs and sup-
plements (HDS)-induced ACLF show an increasing 
trend (1, A).
 2.4.4.  The unknown causes for acute insult and chronic 
injury constitute only 5–15% cases of ACLF in the 
East in contrast to the West, where these are seen 
in about 40% of ACLF patients (1, A).
ACLF is distinct from acute decompensation (AD): 
differentiating AD and ACLF
The two disease entities look similar and are often misunder-
stood. The experts reviewed the literature and presented their 
data. The data from the AARC database were presented. The 
discussion revolved around the following main issues:
Acute decompensation occurs in a cirrhotic with or 
without prior decompensation and is often associated with 
a precipitant [6]. The presentation of AD is either hepatic 
(jaundice, ascites, HE) or extrahepatic (variceal bleed, acute 
kidney injury or sepsis), and time period is up to 3 months 
[11]. The level of jaundice could be well below 5 mg/dl, 
below the cutoff generally taken for liver failure. The pre-
cipitant for AD can be hepatic (48%) or non-hepatic (46%). 
Ascites/HE/AVB may precede jaundice. There could be 
several combinations in the acute decompensation; such as 
jaundice with or without ascites, HE alone or with ascites 
with or without jaundice, HE variceal bleed alone or with 
ascites, sepsis with jaundice or alone, etc. Each of these enti-
ties is in themselves, a well-defined complication, and has 
been extensively studied in patients with cirrhosis. Moreo-
ver, AD can be the index event or it could be a repeat event 
in patients with prior decompensation. Hence, there are mul-
titudes of combinations possible in a patient presenting with 
AD. After due deliberations, it was unanimously felt that AD 
should be considered as a recordable time point, an unfa-
vorable event, in the natural history of cirrhosis rather than 
a syndrome by itself. The precise type of acute presentation 
of the patient should be recorded and the patient should be 
accordingly monitored and managed.
The overall mortality in patients with AD at 1 and 
3 months was 23% and 29%, respectively, much lower than 
when patients develop ACLF. The probability of reversal, 
progression to end-stage liver disease and need for a liver 
transplantation would depend on the presentation of the AD 
such as variceal bleed or ascites. Role of bridging therapy 
and emerging therapies in AD is largely unknown.
Acute-on-chronic liver failure (ACLF) is a syndrome of 
hepatic decompensation (jaundice, coagulopathy, ascites 
and/or HE), where the insult is only hepatic and leads to liver 
failure in a period of 4 weeks [2]. Jaundice and coagulopathy 
precede development of ascites. Non-hepatic organ failure, 
i.e., AKI, sepsis, AVB develops after the ACLF syndrome or 
less commonly, with the onset, depending on the severity of 
liver failure. The presentation is index, occurring in a patient 
of chronic liver disease with or without underlying cirrhosis 
of the liver. The hepatic reserve may show recovery leading 
to complete reversal of the syndrome as well as regression of 
fibrosis and portal hypertension. The long-term survival, i.e., 
after 24 months of index presentation with ACLF is better 
than the AD cohort [HR: 1.94 (1.17–2.21), p < 0.01] [76]. 
The progression of disease and onset of multi-organ failure 
are faster in the non-salvageable cohort with a high 3-month 
mortality of 54% [77].
Development of ascites represents a state of acute por-
tal hypertension in ACLF patients. This rapid rise in portal 
pressure is a result of severe hepatic inflammation and ongo-
ing liver failure. Highly activated stellate cell population, 
cytokine storm and ongoing hepatic parenchymal necrosis 
perpetuate the portal hypertension syndrome. The use of 
non-selective beta-blockers has been shown to be effective 
in reducing the mortality and risk of variceal bleed in ACLF 
patients.
ACLF is a unique disease entity and is distinct from 
acute decompensation by considering only those patients 
who have one type of AD and in a specified time frame of 
28 days; this includes patients who develop after a hepatic 
insult, jaundice and coagulopathy followed by develop-
ment of acute portal hypertension in the form of ascites 
and or HE (Table 3).
Recommendations
 2.5.  ACLF is distinct from acute decompensation (AD): 
differentiating AD and ACLF.
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 2.5.1.  Natural history and outcome of ACLF.
 2.5.1.1.  The main etiologies for ACLF are alcohol-related 
injury, viral hepatitis, drug-induced liver injury, 
and autoimmune liver disease. In the Asian Pacific 
region, in only about 5–10% of the cases, the acute 
insult is unidentifiable [1, A].
 2.5.1.2.  Age and the presence of cirrhosis are independent 
risk factors for mortality in ACLF (1, B).
 2.5.1.3.  Portal hypertension with an HVPG greater than 
18 mmHg and/or variceal bleeding, presence of 
complications including ascites, SBP and encepha-
lopathy are independent predictors for mortality (2, 
B).
 2.5.1.4.  Starting NSBBs is safe in ACLF and its use is asso-
ciated with improved short-term survival (2, B).
 2.5.1.5.  Appropriate management has key impact on the 
outcomes of ACLF, early (within 2 weeks) anti-
HBV treatment for HBV-ACLF, corticosteroid 
therapy for alcoholic ACLF and AIH-ACLF are 
worthwhile options (1, B).
 2.5.2.  Natural history and outcome of acute decompen-
sation.
 2.5.2.1.  Acute decompensation (AD) is currently defined 
as acute occurrence of decompensating events 
(ascites, HE, jaundice, variceal bleed or bacterial 
infection) in a patient with CLD (1, B).
2.5.2.2. Patients with AD who have or progress to develop 
extrahepatic organ failure have high short-term 
mortality (1, A).
2.5.2.3. Early evaluation of potential predictors and precipi-
tating agents can help in managing these patients 
(1, B).
 2.5.3.  Acute decompensation—differentiating from 
ACLF for clarity in definition.
 2.5.3.1.  AD develops in a patient with chronic liver disease/
cirrhosis, with or without prior decompensation, 
and is often associated with an identifiable precipi-
tant and develops in less than 3 months [2, A].
 2.5.3.2.  Any decompensation preceding jaundice strongly 
favors AD [1, B].
 2.5.3.3.  Absence of repeated episodes of decompensation 
differentiates ACLF as a unique syndrome [2, A]. 
This has implication on the management decisions 
and prognostication, including reversibility of the 
syndrome.
 2.5.3.4.  Long-term survival, reversal and/or recovery of 
hepatic reserve has been documented with ACLF 
[2, A].
 2.5.4.5.  The differentiating features between different pres-
entations of AD and the ACLF need to be studied 
carefully by expanding the AARC database [3, C].
Role of Liver histology in ACLF
Since the previous consensus statement, new data and 
insights into the liver histopathology have become available. 
The main questions that were addressed in the current con-
sensus meeting were: (1) Is liver biopsy feasible and safe in 
ACLF, (2) Can liver biopsy help to differentiate ACLF from 
ALF and chronic liver disease, (3) Are there any histologi-
cal predictors of outcome in ACLF, such as need for liver 
transplantation or mortality and (4) Are there any differences 
in regenerative response in sequential biopsies of survivors 
and non-survivors?
Percutaneous liver biopsy is generally not feasible in 
patients with ACLF due to coagulopathy and ascites. Tran-
sjugular liver biopsy (TJLB), on the other hand, is consid-
ered relatively safe and can help assess stage of fibrosis and 
severity of hepatic injury. For example, severity of alcoholic 
hepatitis in alcoholic liver disease-related ACLF could be 
assessed only by liver biopsy [63]. It can provide clues to the 
underlying acute insult as in Wilson’s disease, malignancy, 
autoimmune hepatitis, DILI and NASH [78, 79].
Table 3  Differentiating ACLF from acute decompensation
Parameter(s) Acute-on-chronic liver failure (ACLF) Acute decompensation (AD)
Presentation Hepatic insult
Index
Hepatic or non-hepatic
Can be index or subsequent
Identifiable precipitant In up-to 95% cases In up to 70% cases
Time from insult to presentation Within 4 weeks Up to 12 weeks
Underlying cirrhosis May or may not be present Always present
Prior decompensation No With or without Prior Decompensation
Mortality at 1 and 3 months 33–51% 23–29%
Reversal or recovery In half of cases Uncommon
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Mini-laparoscopic liver biopsy is another alternative 
for getting liver biopsy in patients of advanced cirrho-
sis with acceptable bleeding risk. More data needed on 
this modality and comparison with TJLB are lacking at 
present. However it can be considered in areas with poor 
access to TJLB and biopsy is definitely needed for the 
decision- making [80].
Differentiating ALF and chronic hepatitis with flare 
is based on findings of fibrous bands (spurs and bridges) 
and ductular proliferation. Features of cholestasis and 
bile duct proliferation are more common in patients with 
acute injury (classical features of acute hepatitis along 
with cellular and ductular cholestasis are indicative of 
acute injury). Differentiation between cirrhosis with acute 
deterioration and compensated cirrhosis is based on the 
presence of necrosis and features of acute hepatitis in the 
former group of patients [63]. It was proposed that the 
diagnostic stains for fibrosis and necrosis be mentioned. It 
was also proposed that connective tissue stains (especially 
Shikata’s orcein) should be done in all such cases for dif-
ferentiating necrosis from fibrosis.
Liver histopathology could be very useful in prognos-
ticating the outcome in a patient with ACLF [63, 81]. The 
extent of necrosis, liver damage and fibrosis is helpful. The 
presence of ductular bilirubinostasis on liver biopsy defined 
as the presence of bile plugs in dilated ductules at the inter-
face between the portal tract and parenchyma predicted a 
poor outcome and a high potential for development of infec-
tions in ACLF. While ballooning was helpful, suggestive of 
regenerating potential, the presence of eosinophilic degen-
eration of hepatocytes was not a favorable feature. Standardi-
zation of liver biopsy assessment is essential for a uniform 
approach to the diagnosis and treatment of CLD and acute 
insult.
Liver regeneration is considered to play an important 
role in ACLF as prognosis can be improved if the critical 
threshold of functional liver cell mass is regained. Decom-
pensated cirrhosis is considered irreversible owing to loss 
of regeneration potential. Liver histology can provide mor-
phological evidence supporting these concepts and for 
assessing regenerative potential and prognosis [82]. In this 
report, immuno-histochemical study of two levels of regen-
erative responses in liver failure revealed that proliferating 
hepatocytes were significantly more in ALF in comparison 
to ACLF (p < 0.001) and CLD (p < 0.001).
There is significant relationship between HSCs and pres-
ence of HPCs, indicating a possible dynamic role of HSCs 
in liver regeneration and pathobiology of ACLF [83]. Liver 
biopsy is an important mode of understanding and validat-
ing the results of clinical trials exploring various therapeutic 
options for, e.g., mobilization of bone marrow-derived stem 
cells with granulocyte colony-stimulating factor (GCSF) 
[84].
Recommendations
 2.6.   Role of liver histology in ACLF.
 2.6.1.  A liver biopsy through the transjugular route is 
helpful to diagnose/confirm the cause of acute 
injury [1, B].
 2.6.2.  Liver biopsy is helpful in patients where the pres-
ence and stage of underlying chronic liver disease 
and/or the cause of chronic liver disease are not 
clear (2, A). Biopsy can help identify unsuspected/
multiple etiologies, i.e., primary and concomitant 
etiologies.
 2.6.3.  The need of liver biopsy in ACLF should be indi-
vidualized, especially in alcoholic hepatitis, severe 
autoimmune hepatitis, and flare of Wilson disease 
(2, A).
 2.6.4.  Liver biopsy indicates the stage of fibrosis and is 
helpful in the prognosis and outcome in patients 
with ACLF (B 1). It can help in distinguishing 
ACLF from decompensated cirrhosis [1, B].
 2.6.5.  Certain histologic parameters are predictors of 
prognosis of ACLF, like ductular bilirubinostasis, 
eosinophilic degeneration, and parenchymal extinc-
tion (1, B).
 2.6.6.  It can help in distinguishing ACLF from decom-
pensated cirrhosis [1, B].
 2.6.7.  Standardization of liver biopsy assessment is essen-
tial for a uniform approach to the diagnosis and 
treatment for CLD and acute insult (2, C).
 2.6.8.  Noninvasive tools to measure liver stiffness and 
biomarkers may help in identifying patients with 
advanced fibrosis. Studies are needed to validate 
the performance of these tests in the setting of 
ACLF (2, C).
Defining the liver failure in ACLF
Acute liver failure is generally defined as development of HE 
within 4 weeks of onset of jaundice [1, 2]. Since the basic 
premise in ACLF is to identify patients with chronic liver 
disease or cirrhosis presenting as acute liver failure, the time 
frame for liver failure was kept as 4 weeks [5].
The clinical presentations in ACLF is varied and depends 
upon the severity of acute insult and degree of underlying 
chronic liver disease. In the published reports, patients 
included as having ACLF had severe jaundice associated 
with organ failure manifested as either HE or hepatorenal 
syndrome (HRS) [1, 2].
Defining the liver failure in ACLF, therefore, required a 
detailed consideration of all the existing liver failure scores 
and the criteria defining liver failure in the organ failure 
scores such as SOFA and APACHE II. The two main vari-
ables are bilirubin and coagulopathy.
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Serum bilirubin analysis of the AARC data revealed 
that patients with a bilirubin between 5 and 10 mg/dl also 
had substantial mortality ranging around 38%. The data 
for patients below this level were, however, not collected 
as per the initial definition, but is likely to yield mor-
tality rates much below 33%. On the other hand, in the 
CANONIC study, the level of bilirubin for hepatic failure 
was taken as 12 mg/dl so as to determine 15% mortality at 
28 days. If these criteria were applied to the ACLF patients 
in the Asian region, a much higher mortality was observed 
in this cohort. After detailed discussion, the original value 
of > 5 mg/dl was accepted as the cutoff for bilirubin for 
defining liver failure [1, 2]. This was reiterated to be inclu-
sive of less severe group of patients and enabling a com-
plete spectrum of patients, including those who have a 
potential for recovery [2].
Coagulopathy the presence and degree of coagulopathy 
as a marker for liver failure were re-evaluated. Coagulopathy 
is an important hallmark of severe hepatic dysfunction [59, 
60]. Patients with ACLF have complex hemostatic defects 
leading to a delicate, unstable balance between bleeding and 
thrombosis [85].
Development of clinical ascites and/or encephalopathy 
has been conventionally taken as evidence of hepatic failure 
[1, 27]. Ascites and HE were not seen in all the patients and, 
therefore, presence of either of them was accepted for the 
definition of ACLF. In the AARC data, ascites was present 
in 91% and HE in about 45% of the patients at presentation.
The data were further analyzed to see if a shorter interval 
of 2 weeks instead of 4 weeks is a better cutoff for pre-
dicting mortality in patients with underlying cirrhosis who 
developed jaundice followed by ascites. The analysis of the 
AARC data showed that in patients who developed ascites 
within 2 weeks against those after 2 weeks of onset of jaun-
dice, though had a slightly more severe course, the differ-
ences in mortality were not significant.
Grade of liver failure for ACLF like in many conditions 
in medicine, such as the NYHA classification for heart fail-
ure [86] severity of a disease or variable can be defined to 
predict the outcome of the disease. Using the four variables, 
bilirubin, INR, ascites and HE, a simple scoring system may 
be helpful for making treatment strategies.
The basic premise for defining a syndrome is to iden-
tify a group of patients, who have a distinct presentation, 
course and outcome. A prospective study using AARC data-
base with 1402 patients from several centers across Asia 
included a large derivation cohort of 480 patients to develop 
a dynamic prognostic model, which was validated in subse-
quently enrolled 922 patients to predict outcomes including 
mortality [3]. The results bring forth a simple ‘liver fail-
ure grading system’ for patients with chronic liver disease 
based on variables, namely serum bilirubin, INR, grade of 
HE, serum lactate and serum creatinine [43, 87–89]. Serum 
lactate levels are elevated in relation to degree of hepatocel-
lular injury, inflammation and degree of tissue perfusion.
The analysis resulted in a simple ‘liver failure grading 
system’ based on 5 variables; namely, serum bilirubin, INR, 
serum lactate, serum creatinine and grade of HE. There is 
no score dedicated to liver failure in cirrhotic patients, com-
monly recognized as a distinct entity, ACLF. The grading 
system, i.e., Grade I for a score of 5–7, Grade II for 8–10 
and Grade III for 11–15 with 28-day mortality of 12.7, 44.5 
and 85.9%, respectively, was developed. The grades of liver 
failure showed a potentially recoverable group (Gr. I), a 
group that needs special monitoring (Gr. II) and a group 
that demands immediate interventions for improved outcome 
(Gr. III). The AARC model was found to be better than exist-
ing models for ACLF with an excellent predictability, i.e., 
in AUROC of 0.80 (derivation cohort) and 0.78 (validation 
cohort). It is even more robust than recently reported models 
[3] where the AUROC is below 0.80. The AARC-ACLF 
score is dynamic in nature. It could predict day 7 (score of 
9 or below) and day 28 survival at presentation (score of 9 
or below). For a baseline score of ≥ 10, with each one unit 
increase, the day 7 mortality increased sharply compared 
to the patients who presented with a score of < 10 (20% vs. 
4%). The score also predicted well the day 28 and day 90 
survival. Thus, the AARC score provides a physician a win-
dow to decide early and explore definitive therapies includ-
ing liver transplantation. Shift from grade I to III liver failure 
at day 4 and day 7 increases the mortality significantly. At 
the same time, the persistence of grade I or II liver failure 
till day 7 predicted improved survival, while persistence in 
grade III failure was uniformly severe and warranted early 
consideration for transplant [3].
Recommendations
 3.0.  Defining the liver failure in ACLF:
 3.1.  Jaundice (serum bilirubin > 5 mg/dL [> 85 lmol/L]) 
and coagulopathy (INR > 1.5 or prothrombin activ-
ity < 40%) are mandatory parameters to assess liver 
failure (1, A).
 3.2.  Ascites and/or encephalopathy as determined by physi-
cal examination also reliably reflect significant hepatic 
functional impairment (1, A).
 3.3.  Liver failure score (AARC score) which includes total 
bilirubin, INR, grade of HE, plasma lactate and serum 
creatinine reliably predicts the disease severity and 
outcome (1, A).
 3.4.  Grading of liver failure as per AARC score I (5–7), 
II (8–10), III (11–15) effectively prognosticates and 
guides the therapy [1, B].
 3.5.  The assessment of coagulation system by global coagula-
tion methods (viscoelastic technique/thrombin genera-
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tion test) may be considered as a useful tool for assessing 
coagulation anomalies in ACLF patients (2, B).
Sepsis in ACLF
Sepsis is a syndrome of systemic inflammatory response of 
the host to an identifiable infection. The systemic inflamma-
tory response syndrome (SIRS) is defined by the presence of 
at least two of the following criteria: (1) altered temperature, 
(2) elevated respiratory rate or hyperventilation, (3) tachy-
cardia, and (4) altered white blood cell count (high, low, or 
immature forms) [67]. Sepsis is the most common cause of 
mortality in most intensive care units (ICUs) [90–92].
Due to the hyperdynamic circulation and complications 
of portal hypertension, the currently accepted clinical defi-
nition of SIRS and sepsis may not be entirely applicable 
to patients with cirrhosis or ACLF. Hence, a high index of 
suspicion is required for making a clinical diagnosis of sep-
sis in these patients. Liver failure initiates and predicts the 
development of SIRS. New onset SIRS in the first week is an 
important determinant of early sepsis, organ failure, and sur-
vival (Fig. 3). Prompt interventions in this ‘golden window’ 
before development of sepsis may improve the outcome of 
ACLF [78].
Consideration of sepsis as an acute insult in the absence 
of liver failure is confusing and with limited scientific basis. 
Sepsis is a consequence rather than the cause for develop-
ment of ACLF. The APASL definition does not include sep-
sis as a primary cause for liver failure, but in the Western 
definition, sepsis is considered as the most common pre-
cipitant. The inclusion of sepsis in the definition is likely to 
be associated with concomitant multi-organ involvement, 
poor prognosis and would be unlikely to provide a targeted 
therapy or a definitive therapy such as liver transplant.
SIRS is the inflammatory response to the damaged 
organ in the host. It could be a result of sterile inflam-
mation or an occult infection [93–95]. In fact, in 60% of 
patients fulfilling the SIRS criteria, infection could not be 
detected [78]. This highlights the limitations of the cur-
rent techniques available to detect infections or may be 
because of use of prophylactic antibiotics the detection of 
organisms becomes difficult. Prevention of development 
of SIRS or its progression from SIRS to sepsis by immune 
modulation in the ‘Golden Window’ period could decrease 
the incidence of organ failure and improve survival [78]. 
‘Golden window’ is a short period of about 1 week before 
the onset of sepsis and development of extrahepatic organ 
failure in a patient with ACLF. Therapeutic interventions 
during this period are likely to prevent organ failure and 
provide a potential opportunity for ameliorating or revers-
ing the hepatic injury and failure [78].
The current paradigm regarding the host immune 
response to sepsis is debated and is a matter of great 
interest in clinical trials as well as basic science. Two theo-
ries have been proposed to describe the host response to 
sepsis. According to the most accepted theory, both pro-
inflammatory and anti-inflammatory responses occur early 
and simultaneously in sepsis although the net initial effect 
of these competing processes is typically manifested by an 
early, dominant, hyperinflammatory phase characterized by 
shock, fever and hypermetabolism [96, 97]. Subsequently, 
this initial hyperinflammatory phase evolves over several 
days into a more protracted immunosuppressive phase [98]. 
The robustness of the hyperinflammatory phase depends on 
numerous factors, including pre-existing co-morbidities, 
nutritional status, microorganism load and virulence fac-
tors [99, 100].
According to the second theory, there is rapid and sus-
tained upregulation of genes that regulate the innate immune 
response and the simultaneous downregulation of genes that 
regulate the adaptive immune response. There is protracted, 
unabated inflammation driven by the innate immune system 
with resultant organ dysfunction and failure [101].
Whether sepsis is the cause or a result of liver failure 
was debated at length. The fact that patients who presented 
with no SIRS or subsequently developed SIRS or sepsis over 
a period of 1–2 weeks indicates that infection and sepsis 
develop after liver failure and unabated inflammation leads 
to immune paresis and provides an opportunity for infec-
tions and sepsis to occur. Non-hepatic infections are also 
common in patients with ACLF [101, 102]. Neutrophil dys-
function and immune paralysis due to reduced HLA-DR 
expression have been shown to rapidly develop in ACLF 
patients [102–104]. The frequency of intrahepatic myeloid 
and plasmacytoid dendritic cells is reduced with increased 
interferon gamma producing CD8 T cells in patients with 
SIRS  Sepsis Organ Failure
7 Days
Fig. 3  Golden window in ACLF. ACLF is the state of acute inflam-
matory response with cytokine burst. The SIRS is a response to this 
inflammation and subsequent resolution of inflammation and recov-
ery or persistence of inflammation (leading to Compensatory Anti-
inflammatory Inflammatory Response Syndrome-CARS) and sepsis. 
Patients of ACLF in a period of 7 days develop SIRS (which can be 
infective or sterile) but both the things lead to complications and sep-
sis develops subsequently. This time period is the therapeutic Golden 
Window. SIRS needs consideration for organ support, antibiotics for 
occult sepsis and prioritization for definitive therapy, i.e., liver trans-
plant
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ACLF. Decreased frequency of DCs and high IFN-γ levels 
correlate with poor patient survival [104].
Bacterial infection is present in about 1/3rd of ALCF 
patients at presentation to a tertiary referral hospital, and 
this further increases by first week [78]. The AARC data 
showed that the patients presenting with sepsis, at baseline 
or who developed new sepsis at day 4, have high mortal-
ity. Bacterial infection (BI) predicts development of organ 
failure in ACLF. Organ dysfunction and organ failure are 
significantly higher in infected cohort with high short-term 
mortality. The acute phase proteins, such as C-reactive pro-
tein and procalcitonin, were proven to be reliable biomarkers 
for bacterial infection. The most frequent infections are SBP, 
pneumonia, UTI, and bacteremia. Second infection (2nd hit) 
is associated with poor outcome in patients with ACLF. Hos-
pitalized patients with ACLF should be monitored closely 
for the presence of infections to enable early diagnosis and 
treatment. Routine examination of blood and body fluids is 
recommended. Patients who respond to treatment for bacte-
rial infection have significantly reduced mortality. Patients 
who respond to treatment for bacterial infection have sig-
nificantly reduced mortality. As soon as bacterial infection 
is diagnosed or suspected, broad spectrum antimicrobial 
agents or combined use of antibiotics are preferred, there-
after the therapy is adjusted according to the results of 
the sensitivity test. Empirical antibiotic therapy should be 
based on environment, local resistance profiles, severity and 
type of infection. To optimize the empirical antibiotic treat-
ment, it is quite important to distinguish among community 
acquired, health care associated and nosocomial infections.
Invasive fungal infection is not uncommon in ACLF 
patients. However, data are minimal. The diagnosis of inva-
sive fungal infection can be proven, probable or possible, 
depends on mycological evidence, and clinical evidence. 
Invasive pulmonary aspergillosis (IPA) is increasingly rec-
ognized as a cause of morbidity and mortality in patients 
with ACLF. Prophylaxis of invasive fungal infection may be 
applicable with echinocandins in selected patients. Prophy-
laxis with fluconazole followed by echinocandins needs to 
be evaluated in ACLF patients. Predictors of poor progres-
sion (risk factors) include diabetes, AKI, ICU admission, 
and admission for bacterial infection, prolonged antibiotic 
therapy (> 5 days from admission), prior h/o hospitaliza-
tion. Biomarkers such as galactomanan or B–D Glucan can 
be used for supporting diagnosis if there is invasive fungal 
infection in ACLF. Administration of albumin is recom-
mended in patients with SBP for preventing from type-1 
HRS and reducing mortality. The role of albumin in prevent-
ing or treating other infections in ALCF is not clear.
Recommendations
 4.0.  Sepsis in ACLF.
 4.1.  There is a central role of inflammation and dysbalance 
of innate and adaptive immune responses in ACLF 
patient (1, B).
 4.2.  It is difficult to differentiate SIRS from early sepsis in 
cirrhosis (2, A).
 4.3.  Bacterial infection is present in about 1/3rd of ALCF 
patients at presentation to a referral hospital, and this 
may increase in the first week [2, B].
 4.4  Patients who do not have sepsis have low 28-day mor-
tality [B2]. Patients with accompanying sepsis at base-
line or who develop sepsis at day 4 have high mortality 
[2, B].
 4.5  Organ dysfunction and organ failure are significantly 
higher in infected cohort and this is attended with high 
short-term mortality [2, B].
 4.6  Bacterial infection (BI) is an important factor to pre-
dict development of organ failure in ACLF. The most 
frequent infections are SBP, pneumonia, UTI, and Bac-
teremia (1, A).
 4.7  Second infection (2nd hit) is associated with poor out-
come in patients with ACLF [1, B].
 4.8  Hospitalized patients with ACLF should be moni-
tored closely for the presence of infections to enable 
early diagnosis and treatment. Routine examina-
tion of blood and body fluids is recommended (1, A).
 4.9  The acute phase proteins, such as C-reactive protein 
and procalcitonin, have been proven to be reliable 
biomarkers associated with infection and are recom-
mended for screening for the presence of bacterial 
infections (1, B).
 4.10  As soon as bacterial infection is suspected or diag-
nosed, broad spectrum antimicrobial agents alone 
or in combination should be started and thereaf-
ter, the therapy should be adjusted according to the 
results of the antibiotic sensitivity test results (1, A).
 4.11.  Empirical antibiotic therapy should be based on envi-
ronment, local bacterial resistance profiles, severity 
and type of infection. To optimize the empirical anti-
biotic treatment, it is quite important to distinguish 
among community acquired, health care associated 
and nosocomial infections (2, A).
 4.12.  Invasive fungal infection is not uncommon in ACLF 
patients. These can be proven, probable or possible, 
depending on mycological and clinical evidences (2, 
B). Biomarkers such as galactomanan or B-D glucan 
can be used for supporting the diagnosis (1, B).
 4.13.  Invasive pulmonary aspergillosis (IPA) is increasingly 
recognized as a cause of morbidity and mortality in 
patients with ACLF. Voriconazole plasma concentra-
tion monitoring may ensure the safety and efficacy of 
ACLF patients with Invasive aspergillosis infection (2, 
C).
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 4.14.  Prophylaxis of invasive fungal infection can be done 
using echinocandins in selected patients (B2). Proph-
ylaxis with fluconazole followed by echinocandins 
needs to be evaluated in ACLF patients [1, C].
 4.15.  Predictors of poor progression (risk factors) of fungal 
infections in ACLF are the presence of diabetes, AKI, 
ICU admission, and admission with bacterial infection, 
prolonged antibiotic (> 5 days pre-admission) and prior 
hospitalization (2, B).
 4.16.  The value of qSOFA and Sepsis-3 criteria is unclear to 
assess severity of infection in patients with ACLF.
 4.17.  Administration of albumin is recommended in patients 
with SBP to prevent development of type-1 HRS and 
reduce mortality (A2). The role of albumin in prevent-
ing or treating other infections in ALCF is not clear [2, 
B].
 4.18.  Patients who respond to treatment for bacterial infec-
tion have significantly reduced mortality [2, B].
Organ dysfunction and organ failure in ACLF
The concept to differentiate organ dysfunction from organ 
failure is useful in assessing the degree of organ damage and 
predicting the probability of disease progression or regres-
sion; prioritizing the patient for liver transplantation and the 
likelihood of futility of care or high probability of death.
The data from AARC database were carefully analyzed 
with respect to defining organ dysfunction and organ failure 
for each of the extrahepatic organs.
Renal failure
Renal failure in patients of ACLF is considered to be a com-
plex and challenging condition that is associated with an 
ominous prognosis. Further, kidneys are one of the most 
frequent extrahepatic organs involved in patients with ACLF. 
The EASL-CLIF consortium has defined ACLF in which 
kidney dysfunction is used as a defining condition [11]. 
Hence, renal dysfunction or failure is universally present in 
patients with ACLF with or without liver failure, according 
to the definition by the EASL-CLIF consortium. On the con-
trary; the APASL definition of ACLF does not incorporate 
kidney dysfunction in its definition [1, 2]. Studies based on 
APASL criteria have reported renal dysfunction in 22.8–34% 
of patients with ACLF and as high as 51% using the more 
sensitive AKIN criteria [103]. This highlights the fact that 
a significant number of patients of ACLF based on APASL 
criteria who do not have renal dysfunction (using even the 
most sensitive criteria to detect renal involvement) would 
definitely be missed if renal dysfunction was considered in 
the definition as per CLIF.
In patients with decompensated cirrhosis, the main abnor-
mality causing renal dysfunction is systemic and splanchnic 
vasodilatation secondary to portal (or sinusoidal) hyperten-
sion which leads to decreased effective arterial blood volume 
and activation of neurohormonal systems, the rennin–angio-
tensin aldosterone (RAAS), the sympathetic nervous system 
and non-osmotic release of antidiuretic hormone, resulting in 
sodium and water retention [104–106]. The systemic hemo-
dynamic alterations in ACLF are similar to those in patients 
with decompensated cirrhotics [107], but the pathogenesis 
of renal dysfunction in ACLF is quite different; a major 
role is played by SIRS and subsequent sepsis in patients of 
ACLF but not in those with decompensated cirrhosis [108]. 
A higher prevalence of structural AKI has been reported for 
patients with ACLF. In a large cohort study from the AARC 
database, the concept of PIRO (defined as predisposition, 
infection/inflammation, response, organ failure) was used 
for creating a predictive model for understanding the patho-
physiology of kidney dysfunction in patients with ACLF 
[109]. Together, the components of PIRO reflect the role of 
key factors, which result in development, and progression 
of AKI in patients with ACLF. The PIRO, which is a com-
posite score, derived from the AARC database accurately 
predicted in patients with ACLF, highlighting the prognos-
tic significance of kidney dysfunction in these patients. The 
PIRO score can predict the development of AKI within first 
15 days of diagnosis of ACLF and may help in stratification 
for additional therapeutic interventions [109].
Serum creatinine is used for defining and staging AKI in 
patients with cirrhosis. However, serum creatinine is influ-
enced by various factors, which affect its production and 
excretion, as well as those that impact its measurement and, 
therefore, is unreliable in patients with severe liver dysfunc-
tion including ACLF. The AKI criteria seem more relevant 
as they rely on a dynamic change rather than a static meas-
urement of serum creatinine. A lower value of serum creati-
nine is more relevant in patients with ACLF. Serum creati-
nine above 0.7 mg/dl (as derived from the AARC score) has 
a sensitivity of 78% and specificity of 36% for prediction of 
30-day mortality in patients with ACLF. For the diagnosis 
of kidney failure, the conventional cutoff of 1.5 mg/dl even 
though had a low sensitivity of 48% but had a specificity 
of 99.8% for 30-day mortality. Kidney failure (serum cre-
atinine ≥ 1.5 mg/dl) was seen in 22% of ACLF patients at 
baseline and developed in another 30% within a month. The 
majority of patients of ACLF developed new episodes of 
AKI in the first 2 weeks (11%). Further, the KDIGO defini-
tion for AKI (incorporating the urine output criteria) has 
been shown to be more accurate in determining AKI course 
in critically ill cirrhotics; however, this needs to be evaluated 
for patients with ACLF [110].
Apart from the severity, the course of AKI was seen to 
be an important predictor of clinical outcomes. Almost 80% 
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of the patients, who did not present with AKI at baseline or 
developed within the first 7 days, survived 1 month. How-
ever, in patients who presented with AKI, resolution of AKI 
was associated with a better survival. Progression of AKI 
was associated with highest mortality of 75%. Development 
of new AKI as well as non-resolution or persistence of AKI 
was associated with almost 50% mortality at 1 month in 
patients with ACLF [109].
Kidney injury biomarkers have been studied in patients 
with decompensated cirrhosis; however, their utility in diag-
nosing, staging and understanding the spectrum of AKI 
including the response to therapies has not been carefully 
evaluated in patients with ACLF. There is a potential to look 
at the role of biomarkers of tubular damage, namely N-GAL, 
Kim-1, IL-18 and l-FABP to differentiate functional AKI 
or HRS from structural AKI, i.e., ATN patients with ACLF 
[111] as ATN or structural kidney damage may necessitate 
the need of simultaneous liver–kidney transplant as against 
liver transplant alone for HRS [112].
Treatment for AKI in ACLF depends on the etiology, 
severity, complications, and the presence of other organ fail-
ure and/or hemodynamic status. Targeting the components 
of PIRO, i.e., combating systemic inflammation with anti-
inflammatory strategies (for instance intravenous albumin, 
N-Acetylcysteine), bilirubin reduction, avoidance of nephro-
toxic drugs, aggressive management of circulatory failure 
and maintaining a high mean arterial pressure may prevent 
AKI development and progression in patients with ACLF. 
Albumin intravenous administration has multiple benefits 
volume correction in addition to its anti-inflammatory and 
immunomodulatory properties.
Data on use of vasoconstrictors for AKI in ACLF are 
limited. Terlipressin given as an infusion is superior to 
noradrenaline in the management of HRS-AKI in patients 
with ACLF, but needs extra precaution and close monitoring 
for terlipressin-related adverse effects [111]. The response 
to vasoconstrictor drug is multifactorial and depends on the 
severity of AKI, MELD score and AARC grade [113, 114]. 
Response to vasoconstrictors in AKI in ACLF patients is 
partial and seen in only in about a third of patients. There is, 
therefore, quite often a need for renal replacement therapy 
(RRT). The indications for RRT include severe volume over-
load, hyperkalemia, hyponatremia and worsening metabolic 
acidosis not responding to conservative management [115]. 
Unlike other indications, the threshold for initiating RRT 
should be relatively low, i.e., when AKI occurs as part of 
multi-organ failure or in non-oliguric patients, if the daily 
fluid balance cannot be maintained, Continuous Renal 
Replacement Therapy [CRRT] should be considered [116]. 
The mode of dialysis, i.e., hemodialysis (HD), Slow Low 
Efficient Dialysis (SLED) or CRRT should be chosen based 
on the hemodynamic status of the patient and the expertise 
and availability of the equipment [115, 116].
Recommendations
 5.1.  Renal failure in ACLF.
 5.1.1.  Defining AKI in ACLF.
 5.1.1.1.  AKI criteria (defined as an absolute increase in 
serum creatinine of 0.3 mg/dl within 48 h or by per-
centage increase in serum creatinine of more than 
50% from baseline, which is known, or presumed, 
to have occurred within the previous 7 days) should 
be used for the diagnosis of AKI in patients with 
ACLF [1, A].
 5.1.1.2.  AKIN criteria should be used for the diagnosis and 
prognostication of AKI in ACLF patients (1, B).
 5.1.1.3.  Urine output should be considered to assess the 
stage and course of AKI in patients with ACLF 
admitted to the ICU [2, C].
  5.1.1.4.  In the absence of baseline serum creatinine, AKI 
should be diagnosed based on the cutoff value of 
serum creatinine. A cutoff value of 1.1 mg/dl is 
a reliable marker of significant renal dysfunction 
and 1.5 mg/dl of kidney failure in patients with 
ACLF [1, B].
  5.1.2.  Course of renal failure in ACLF.
 5.1.2.1.  AKI is more common and rapidly progressive in 
patients with ACLF as compared to decompensated 
cirrhosis and is associated with significantly worse 
outcome (1, B).
 5.1.2.2.  Patients with ACLF and AKI have high 30-day 
mortality. The course of AKI is an important deter-
minant of clinical outcomes [1, A].
 5.1.2.3.  Progression of AKI has the worst outcome and 
at the same time resolution is associated with 
improved survival. Both persistence and new devel-
opment of AKI are associated with a high short-
term mortality in patients with ACLF [1, B].
 5.1.2.4.  Serum creatinine levels 1.1–1.5 mg/dl or AKIN 
I are also associated with significant mortality in 
ACLF patients (2, B).
 5.1.3.  Treatment of renal failure in ACLF.
 5.1.3.1.  All attempts should be made to prevent develop-
ment of new AKI in patients with ACLF [1, C].
 5.1.3.2.  Patients with ACLF should be stratified based on 
the PIRO (Predisposition, Infection/Inflammation, 
Response, Organ failure) score for identifying 
patients at risk of AKI development [1, B].
 5.1.3.3.  Targeting the components of PIRO, i.e., combat-
ing systemic inflammation with anti-inflamma-
tory strategies (for instance intravenous albumin, 
N-Acetylcysteine), bilirubin reduction, avoidance 
of nephrotoxic drugs, aggressive management of 
circulatory failure and maintaining a high mean 
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arterial pressure may prevent AKI development 
and progression in patients with ACLF [2, C].
 5.1.3.4.  Data on use of vasoconstrictors for AKI in ACLF 
are limited. Terlipressin given as an infusion is 
superior to noradrenaline in the management of 
HRS-AKI in patients with ACLF (B1). Terlipres-
sin use in ACLF should be carefully monitored for 
adverse effects (1, A).
 5.1.3.5.  Severity of AKI, MELD score and ACLF grade 
predicts therapeutic response to terlipressin and 
albumin in patients with HRS-AKI in ACLF (1, B).
 5.1.3.6.  New treatments should be explored for patients 
with AKI-ACLF looking at systemic inflammation 
as a potential target (2, A).
 5.1.3.7.  Patients with ACLF with AKI persistence should be 
considered for additional pharmacologic interven-
tions to prevent AKI progression and enhance AKI 
resolution [2, C].
 5.1.3.8.  Initiate RRT emergently when life-threatening 
changes in volume overload, hyperkalemia, hyper-
natremia and worsening metabolic acidosis not 
responding to conservative management (1, C). 
The threshold for initiating RRT should be lowered 
when AKI occurs as part of multi-organ failure (1, 
C), or in non-oliguric patients if the daily fluid bal-
ance cannot be maintained.
 5.1.3.9.  Biomarkers of tubular damage, urine NGAL and 
IL-18 need to be evaluated for a role in patients 
with ACLF to determine the need for early RRT or 
artificial liver support (2, C).
Hepatic encephalopathy
The development of HE within 4 weeks of onset of jaundice 
is part of the criteria for defining acute-on-chronic liver fail-
ure (ACLF) [1, 2]. In the recent AARC data, HE was seen to 
be present in about 40% of the patients. Multiple prospec-
tive and retrospective studies had shown that HE in ACLF 
patients is associated with higher mortality, especially in 
those with grade III–IV encephalopathy, similar to that of 
acute liver failure (ALF). The experts proposed and defined 
cerebral dysfunction and cerebral failure as the presence of 
grade I and II HE and Grade III and IV HE, respectively. 
The presence of HE itself increases short-term mortality in 
ACLF as is the severity, i.e., grade of HE [3].
The pathophysiology of HE is complex, and impairment 
of brain energy and development of brain edema appear to 
be central in the pathogenesis of encephalopathy [117, 118]. 
Inflammation plays a greater role in the pathogenesis of HE 
in patients with ACLF than in patients without ACLF and 
is associated with a cytokine storm. Recent data also sug-
gest that neuro-inflammation may have a significant role in 
brain disturbance [117]. Cerebral edema has been observed 
in ACLF, and even low cerebral edema can be detected by 
proper CT and MRI. Vasogenic cerebral edema as detected 
by advanced MRI techniques like magnetization transfer 
ratio (MTR), diffusion tensor imaging (DTI) and diffusion 
weighted imaging (DWI) is common, but rarely requires 
specific treatment [118]. Using advanced MRI techniques, 
Gupta et  al. demonstrated presence of cerebral edema 
increases with severity of ACLF. Correlation between mean 
diffusivity (MD) values and IL-6 levels suggest pathogenic 
role of inflammation in cerebral edema. MELD score and 
MD values in frontal white matter have prognostic signifi-
cance in ACLF [118]. Ammonia, systemic inflammation and 
oxidative stress are key factors in the pathogenesis of HE, 
which may be modulated by glutaminase gene alteration or 
by the presence of spontaneous shunts [118].
Management of HE in hospitalized patients requires 
admission to the ICU and includes—(1) identification and 
treatment of precipitating factors, including infections and 
(2) specific measures for decreasing hyperammonemia 
and systemic inflammation. High volume plasmapheresis 
or albumin dialysis and identification and embolization of 
portosystemic shunts may be required in refractory patients. 
Recently analyzed AARC data showed that ammonia was 
significantly and persistently high in patients with grade III 
and IV HE (p < 0.001). l-Ornithine l-Aspartate (LOLA) 
for Hepatic Encephalopathy has a conflicting role as far as 
HE and ammonia reduction in patients of cirrhosis is con-
cerned. Few recent meta-analysis showed a positive role of 
LOLA in reduction of ammonia as well as improvement in 
encephalopathy. Hence, LOLA can be considered as a poten-
tially beneficial therapy for ACLF patients with HE and/
or hyperammonemia [119]. However, a large prospective 
study would be needed. Emerging therapies include therapy 
for circulatory dysfunction and correction of hyponatremia 
[120].
Ammonia is a simple surrogate marker for HE in ACLF 
and correlates with severity of HE/cerebral failure. In the 
large AARC database, arterial ammonia levels were ana-
lyzed with respect to disease severity and outcome. At 
baseline, ammonia was significantly high in patients with 
cerebral dysfunction (HE grade I–II) and cerebral failure 
(HE grade III–IV). The patients who showed improvement 
in HE grades at day 4 and day 7 showed significant reduc-
tion in plasma ammonia level [121]. Dynamic change in 
ammonia level correlates well with clinical course of HE. 
However, ammonia-targeted therapy needs further trials and 
validation.
Recommendations
 5.2.  Hepatic encephalopathy in ACLF.
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 5.2.1.  HE, including grade 1-2 HE (organ dysfunction) 
and grade 3-4 HE (organ failure), is present in 
about a third of the ACLF patients (2, B).
 5.2.2.  HE with all grades of severity and independent of 
other organ failures is associated with increased 
mortality; the mortality is higher in grade 3–4 
(organ failure) compared with grade 1–2 HE (organ 
dysfunction) [1, B].
 5.2.3.  Inflammation plays a major role in the pathogenesis 
of HE in patients with ACLF and is associated with 
cytokine storm [1, B].
 5.2.4.  Management of HE in hospitalized patients requires 
admission to the high dependency or intensive care 
unit and includes—(1) identification and treatment 
of precipitating factors, including infections, and 
(2) specific measures for decreasing hyperammone-
mia and systemic inflammation. Large volume plas-
mapheresis or albumin dialysis and identification 
and embolization of portosystemic shunts may be 
required in refractory patients [1, C].
 5.2.5.  Ammonia is a simple surrogate marker for HE in 
ACLF and correlates with severity of HE/cerebral 
failure [2, B].
 5.2.6.  Dynamic change in ammonia level correlates well 
with clinical course of HE [2, B].
 5.2.7.  Ammonia-targeted therapy needs further trials and 
validation [2, B].
 5.2.8.  Lactulose, rifaximin, NH3-lowering strategies 
remain the main therapy for HE in patients with 
cirrhosis (1, B).
Coagulation in ACLF
In ACLF, alterations in primary and secondary hemostasis 
result in rebalanced coagulation, which leads to either bleed-
ing or thrombotic episodes [122–125]. In addition, organ 
failures in ACLF may further disturb cirrhotic hemostatic 
imbalance. These include circulatory dysfunction [123], sys-
temic inflammatory response syndrome [124, 125], sepsis, 
endogenous heparin-like substances or heparinoids [126] 
and renal dysfunction [127, 128].
Coagulation system in liver diseases is usually assessed 
by INR and platelet counts. Study by Premkumar et al. [129] 
and Blasi et al. [130] suggests that the ACLF is a hypocoagu-
lable and hypofibrinolytic disorder and development of SIRS 
[131, 132] and sepsis further increases the hypocoagulability 
in these patients with increased chances of coagulopathic 
bleeding. Indirect evidence suggests that the endogenous 
heparinoids in ACLF patients with SIRS and sepsis could 
induce increased hypocoagulable state [130]. Conventional 
tests are insensitive to assess the complex coagulopathy in 
ACLF can be further complicated by SIRS and sepsis. The 
development of SIRS by day 7 further increases the INR 
(p < 0.001); however, no effect on platelets has been noted. 
ACLF cases with sepsis at presentation show increased INR 
and low platelets. Studies indicate the decline of platelets in 
first week associated with increased chances of organ failure 
and short-term mortality [131]. Acute variceal bleed at the 
time of presentation did not have association with baseline 
platelet counts; however, the INR was significantly higher in 
bleeders than non-bleeders in the recently analyzed AARC 
data.
PT-INR or prothrombin times is useful for prognostica-
tion, but are insensitive for detection of coagulopathy. More 
evidence-based algorithmic approach is needed for diagnosis 
and management of ACLF-induced coagulopathy.
Recommendations
 5.3.  Coagulation in ACLF.
 5.3.1.  ACLF is a hypocoagulable state and this can get 
escalated with the development of SIRS and sepsis 
[2, C].
 5.3.2.  Traditional coagulation measures, including pro-
thrombin time (PT), activated partial thrombo-
plastin time (aPTT), international normalized ratio 
(INR), fibrinogen levels and bleeding time (BT) do 
not measure bleeding risk in ACLF [2, B].
 5.3.3.  Coagulopathy assessment and management in 
ACLF should be guided based on global coagu-
lation assessment system [ROTEM/TEG/SONO-
CLOT] [2, C].
 5.3.4.  Patients need to be characterized as bleeding or 
thrombosis phenotype by clinical assessment of 
major bleeding and d-dimer assay, respectively 
[2, C].
 5.3.5.  Global viscoelastic tests (TEG/Sonoclot/
ROTEM) provide a more physiologic assess-
ment of coagulation and should be considered 
to guide blood transfusion requirements in liver 
transplantation [1A] and other major surgery 
[2B] and invasive procedures [2C]. Application 
of global viscoelastic testing with ACLF in the 
ICU setting requires more data [2C].
Portal and systemic hemodynamics in ACLF and variceal 
bleed
Portal hypertension in liver disease is associated with both 
structural damage, which is the irreversible component, and 
dynamic component that includes increase in cytokine pro-
duction, endothelial dysfunction, impaired vasorelaxation, 
and impaired vascular relaxation, which may be reversible 
component in the pathophysiology of portal hypertension 
after recovery. Thus, increased portal pressure in ACLF not 
only contributes to variceal bleeding but also to development 
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of rapid onset ascites and other systemic complications 
including organ failures of ACLF. Majority of the patients 
with ACLF die during the first 45 days (median time to death 
15 days) since the diagnosis [132]. ACLF patients have been 
shown to have much higher HVPG as compared to com-
pensated cirrhotics. Among survivors of ACLF, complica-
tions such as ascites, coagulopathy gradually regress by 3 
months [133]. It is thus likely that in patients with ACLF, 
the portal pressure gets acutely elevated and, after recovery, 
hepatic inflammation and cytokine levels decrease, which 
leads to improvement in hepatic as well as systemic hemo-
dynamics. This was also indicated in a recent Asia Pacific 
multi-center study that higher cardiac output correlated with 
30-day mortality (p < 0.019) and higher HVPG was associ-
ated with increased risk of variceal hemorrhage and mortal-
ity at 30 (p < 0.02) and 90 days (p < 0.001) [133]. Notably, 
these features were more pronounced in alcoholic hepatitis 
patients [134]. Choudhury et al. showed that baseline HVPG 
and mean pulmonary artery pressure were independent pre-
dictors of three-month mortality in ACLF [135].
Variceal progression and  role of  pharmacotherapy 
in ACLF The rapid development of varices and bleeding is 
a matter of great concern in ACLF patients. It is important 
to determine the need of acute portal pressure reduction in 
these patients. It is likely that the patients would benefit 
from portal hypertension-reducing drugs like beta-blockers, 
especially in the acute phase of portal hypertension. NSBB 
have beneficial effects on the severity of portal hyperten-
sion, which requires both the beta-1 and beta-2 actions of 
the drug to ameliorate splanchnic vasodilation and high car-
diac output.
Patients on NSBB had less severe grade of ACLF and 
a slower progression of ACLF during the study period. 
Patients who were receiving NSBBs in the previous 
3 months and discontinued NSBBs (n = 78) after develop-
ment of ACLF had a higher mortality (37% vs. 13%) and the 
main difference between those who discontinued or did not 
discontinue BB was the presence of circulatory dysfunction 
(hypotension requiring pressers) and respiratory failure. In 
another RCT comparing carvedilol with placebo in patients 
with ACLF (defined by APASL criteria) with either no or 
small esophageal varices and no contraindication to carve-
dilol use, carvedilol was found to reduce mortality, develop-
ment of SBP and AKI at week 4 [135]. Thus, it is clear that 
patients should be continued on NSBBs, if feasible, even if 
ACLF develops [136].
Regarding the safety and radiation exposure of technical 
procedures for hepatic hemodynamics, Hari et al. studied the 
safety profile of HVPG measurement prospectively [137]. 
Accordingly, HVPG procedure showed a good safety profile 
and the radiation exposure was in most of the cases low. 
However, the HVPG measurement is invasive and difficult 
for routine clinical practice. Therefore, non-invasive surro-
gates that correlate well with invasive HVPG measurements 
are urgently needed in patients with ACLF [137–139].
PICD incidence, presentation, diagnosis and  management 
in  ACLF Ascites is one of the syndrome defining com-
ponents and in the AARC study, about 91% patients had 
ascites at presentation. About one-third of the patients pre-
senting with ACLF do require paracentesis for severe grade 
ascites [140]. The presence of ascites in ACLF is different 
in many aspects from decompensated cirrhosis or AD [141]. 
Development of PICD in ACLF is associated with very high 
mortality. Albumin infusion was shown to significantly 
reduce mortality. Albumin infusion also helped in reducing 
to nearly half the incidence of development of new com-
plications such as hyponatremia, hepatic encephalopathy 
and acute kidney injury. A high PRA level in ACLF patient 
reflects state of severe systemic inflammation, high portal 
pressure and systemic circulatory dysfunction [142, 143].
All precautions and monitoring including plasma renin 
activity are needed in undertaking ascetic tap in ACLF 
patients. Ascites in ACLF is part of acute portal hyperten-
sion and large volume paracentesis significantly alters the 
hemodynamics. Pharmacological agents, such as use of 
vasoconstrictors, should be studied to reduce the incidence 
of PICD in ACLF patients.
Recommendations
 5.4.1.  Systemic, hepatic and pulmonary hemodynamics in 
ACLF.
 5.4.1.1.  Baseline HVPG is an important predictor of mortal-
ity in ACLF (2, B).
 5.4.1.2.  The reduction in HVPG significantly influences the 
management of ACLF (2, C).
 5.4.1.3.  The safety and standardized procedure of HVPG 
measurement should be emphasized. Non-invasive 
surrogates of HVPG need to be investigated in 
ACLF (1, C).
 5.4.2.  Variceal progression in ACLF and role of preemp-
tive BB therapy.
 5.4.2.1.  Increased portal pressure in ACLF can not only 
contribute to variceal bleeding but also other sys-
temic complications and organ failures in ACLF 
[1, A].
 5.4.2.2.  NSBBs may reduce systemic inflammation and may 
have beneficial effects in ACLF patients over and 
above their portal hemodynamic effects [2, A].
 5.4.2.3.  ACLF patients should be started or continued on 
NSBBs, if there are no contraindications [2, B].
 5.4.3.  PICD incidence, presentation, diagnosis and man-
agement.
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 5.4.3.1.  PICD is a result of significant derangement of 
systemic and splanchnic hemodynamics with 
a decrease in effective arterial blood volume, 
which is triggered by large volume paracentesis 
(> 5 L) [1, A].
 5.4.3.2.  PICD occurs in about 80% of ACLF patients when 
a large volume paracentesis is performed without 
additional therapeutic management. However, the 
incidence is reduced when volume expansion with 
albumin is used [1, A].
 5.4.3.3.  Terlipressin, a vasopressin analog, is partially effec-
tive and has been shown to have a synergistic effect 
with albumin in preventing PICD [1, B].
 5.4.3.4.  Non-selective β-blockers, such as propranolol, 
have been suggested to increase the risk of PICD 
and mortality in cirrhotic patients with refrac-
tory ascites. There is lack of data in patients 
with ACLF [2, B].
Prognostic models and disease severity scores 
for ACLF
Prognostic models and disease severity scores
The disease severity assessment is needed for prognostica-
tion and to guide the therapy [144–146]. Disease severity 
scores such as model for end-stage liver disease (MELD) 
have been considered for organ allocation. However, MELD 
score does not take into account cerebral, circulatory and/or 
respiratory failures, thus giving no priority to patients with 
ACLF [147]. The various ICU scores like Sequential Organ 
Failure Assessment (SOFA), Acute Physiology and Chronic 
Health Evaluation (APACHE II) have also been evaluated 
for ACLF patients [147]. A study by Garg et al. in 2012 from 
New Delhi showed the predictability of these scores and also 
the relevance of one, two or more organ failures [28]. Subse-
quently, CLIF consortium has developed CLIF-SOFA score 
for assessing disease severity and prognostication in ACLF 
[11]. We had earlier shown that patients of ACLF have a 
high mortality in the presence of HE and hyponatremia 
in addition to high MELD, APACHE II and SOFA scores 
[28], necessitating inclusion of these parameters. A clinical 
event like HE or the laboratory parameters like bilirubin, 
creatinine, INR, serum sodium, plasma lactate or the liver 
histopathology reports and various disease severity scores 
do give near accurate prognostication.
Furthermore, the available prediction scores have been 
validated at baseline, but none has been evaluated in a 
dynamic manner for prognostication in ACLF patients. 
The severity of ACLF, rapid progression, development of 
sepsis and subsequent multi-organ failure (MOF), poor out-
come with liver transplantation at the onset of MOF needs 
dynamic monitoring. Recent studies support for developing 
a dynamic model that could predict the outcome and appro-
priate time for LT. Chan et al. [147] in 149 patients showed 
that APACHE II scores ≥ 12 and MELD scores ≥ 28 after 
the first week of treatment were independent predictors of 
mortality. Mathurion et al. [148] showed that in the absence 
of response to corticosteroid for AH as assessed by Lille 
score on day 7 and consideration of early LT lead to signifi-
cant cumulative 6-month survival rate (77 ± 8% vs. 23 ± 8%, 
p < 0.001). In large UK and US cohort of severe autoimmune 
hepatitis showed that not the baseline MELD/UKELD but 
the use of corticosteroid and no improvement in MELD/
UKELD scores within 7 days had a poor outcome and sug-
gested early consideration of other strategies including liver 
transplant [149–152]. A dynamic model that could predict 
the reversibility or need for liver transplant is urgently 
required. Early prediction of transplant-free survival, deci-
sion for transplant before onset of sepsis or multi-organ fail-
ure and prioritization for liver transplant could help improve 
the outcome of these patients.
Organ dysfunction and organ failure in ACLF for early risk 
stratification
The CLIF-SOFA and the CLIF-OF (Organ Failure) scor-
ing and the cutoff were developed arbitrarily and included 
patients with hepatic and non-hepatic insults [11]. The 
organ failure was solely derived based on a consensus opin-
ion by the experts [11]. The score is a bit cumbersome and 
becomes predictive of mortality only when extrahepatic 
organ failures are included. Earlier studies [28] and a recent 
study [152] showed that a simple score considering only 
the number of organ failures is easier to recall in predict-
ing mortality in ACLF patients. The recently established 
and evaluated TPPM model in HBV ACLF patients from a 
single center large cohort, which displayed a superior pre-
dictive ability when compared with MELD and MELD-Na 
models [n-153]. TPPMs used TBIL, INR, HBV DNA and 
complications as parameters [153, 154]. Based on current 
multinational cohort, TPPMs demonstrated superiority to 
CLIF-C OFs, CLIF-C ACLFs, MELDs and MELD-Na in 
predicting 28-day and 90-day mortality in cirrhotic HBV-
ACLF patients [155].
The AARC score, as mentioned above, provides a 
physician a window to decide early and explore defini-
tive therapies including liver transplantation (Table 4). A 
patient in whom the AARC score increases from 5 or 6 to 
11 and above (change in grade of liver failure from I to III) 
at day 4 and day 7 increases the mortality significantly and 
a need for emergent transplantation in patients who fulfill 
the criteria. At the same time, the persistence of grade I 
or II liver failure till day 7 predicts improved survival, 
and a possibility of conservative treatment to be effective 
[3] (Fig. 4). AARC score has been compared with other 
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scores for assessing the severity of ACLF such as SOFA, 
CLIF-SOFA, and MELD. The AARC score has been found 
to be superior to the other scores [3] (Fig. 5).
Recommendations
 6.0.   Prognostic models and disease severity scores 
for ACLF.
 6.1.   AARC score and other prognostic models.
 6.1.1.  AARC score is a very good prognostic model for 
the severity assessment and has been adequately 
validated. It has been proven to be superior to 
MELD/MELD Na., CLIF-SOFA and SOFA scores 
for patients with ACLF [2, A].
 6.1.2.  The cumulative mortality increases with rise in 
AARC score in the first week in Grade I (5–7), II 
(8–10) and III (11–15), respectively [2, A].
 6.1.3.  Treatment recommendations for ACLF should be 
based on AARC score. A trend of AARC score 
within first week can predict the need of liver trans-
plant. Score of  < 10 at presentation or decrease in 
score below 10 by the end of first week is associ-
ated with higher chance of survival [1, B].
 6.1.4.  Patients with AARC Score > 10 should be listed 
for LT. Transplant evaluation based on the AARC 
score needs prospective studies [2, B].
 6.1.5.  AARC-ACLF score be estimated at admission in 
patients diagnosed to have ACLF as per AARC-
ACLF definition [1, B].
 6.1.6.  AARC-ACLF score should also be estimated on 
Day 4 and Day 7 to predict the course of illness and 
prognosis [2, A].
 6.1.7.  The TPPM model has a superior predictive value 
for HBV ACLF outcomes than MELD and CLIFF-
SOFA models (2, C).
 6.1.8.  AARC score holds good in predicting the outcome 
in critically ill ACLF patients [1, C]).
 6.1.9.  Lactate should be used for defining the severity of 
the ACLF syndrome. Lactate clearance compared 
to baseline lactate is a better indicator of patient 
status [1, C].
 6.1.10.  There is limited role of Renal Replacement Therapy 
(RRT) & Extra Corporeal Liver Support System 
(ECLS) to treat hyperlactetemia [2, B].
 6.2.   Organ dysfunction and organ failure in ACLF for 
early risk stratification.
 6.2.1.  Organ dysfunction and failure should not be used 
in the definition, but for prognostication in patients 
with ACLF [1, A].
 6.2.2.  Liver failure should be defined by a combination of 
bilirubin and INR and should be classified as mild/
moderate and severe based on AARC as all patients 
have liver failure [1, B].
 6.2.3.  Liver, kidney and brain remain organs of utility in 
patients with ACLF [1, B].
 6.2.4.  Organ dysfunction and failure for brain should be 
based on AARC score [1, C].
 6.2.4.  Respiratory and circulatory failure may be consid-
ered as organs of futility in patients with ACLF 
which may contraindicate liver transplant [1, C].
 6.2.5.  For the diagnosis of organ dysfunction for kidneys 
in patients with ACLF as for patients with cirrho-
sis, AKIN criteria should be used [1, A].
 6.2.6.  Kidney failure should be defined based on serum 
creatinine above 1.5 mg/dl as per the AARC score 
[2, B].
 6.2.7.  The mortality in ACLF increases with the number 
of organ failures (1, C).
Table 4  AARC score and ACLF grade
AARC score
Points Total Bilirubin (mg/dl) HE Grade PT-INR Lactate (mmol/l) Creatinine (mg/dl)
1 < 15 0 < 1.8 < 1.5 < 0.7
2 15–25 I–II 1.8–2.5 1.5–2.5 0.7–1.5
3 > 25 III–IV > 2.50 > 2.5 > 1.5
Minimum-5, Maximum-15
AARC-ACLF grade
Grade Score
I 5–7
II 8–10
III 11–15
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Treatment of ACLF
Antiviral strategies in ACLF HBV reactivation
The presence of high HBV DNA [> 10(5) copies/ml/
or > 2 × 10 (4) IU/ml] is highly sensitive and specific for 
the diagnosis [152]. Early and rapid reduction of HBV 
DNA is the essence of therapy [153]. Several studies have 
indicated that if the reduction in DNA of > 2 logs could be 
achieved within 2 weeks, the survival could be improved. 
This could be related to suppression of hepatocellular 
necrosis and cytokine release [154].
Besides patients who present with ACLF, it is worth-
while that prophylactic therapy should be considered for 
HBsAg-positive patients undergoing chemotherapy [155]. 
There are insufficient data to recommend antiviral therapy 
for HBsAg-negative and anti-HBc-positive patients with 
possible reactivation of occult HBV infection [156, 157].
Recommendations
 7.1.   Antiviral strategies in ACLF HBV reactivation.
 7.1.1   Nucleos(t)ide analogs should be started immedi-
ately in all HBV-infected patients at presentation 
while waiting for confirmation by HBV DNA level. 
Potent antiviral drugs, such as tenofovir, tenofovir 
alafenamide or entecavir, should be used [2,B].
 7.1.2.  Assessment of reduction of HBV DNA level at day 
15 after nucleos(t)ide analogs is encouraged; if < 2 
log reduction, it suggests poor prognosis (2, B).
.
Liver transplantation
A characteristic feature of ACLF is its rapid progression, the 
requirement for multiple organ support and a high incidence 
of short- and medium-term mortality of 50–90%. The 28-day 
mortality rate was 15 times higher in patients with ACLF 
as compared to other chronic liver disease (CLD) patients 
[1–11, 158]. Patients with ACLF are susceptible to infection 
and early transplant-free survival is very low [159, 160]. 
Patients who develop infectious complications (particularly 
pneumonia and/or sepsis) and patients who receive renal 
Fig. 4  Algorithm for management of ACLF. The algorithmic 
approach to ACLF is highlighted based on the severity of liver fail-
ure, acute etiology and specific therapy and dynamic disease course. 
The specific treatment initiated, but if the disease severity is more, 
i.e., AARC Score (consideration of bilirubin, creatinine, INR, lactate 
and HE grade) 11 or more the response is poor with best medical sup-
portive car; hence, early consideration for liver transplant should be 
done, whereas other group needs to be seen for 4–7 days with specific 
therapy and standard medical therapy. Any deterioration or AARC 
score 11 or more needs to consider LT. The presence of extrahepatic 
organ failure needs to be managed, and optimization and improve-
ment need to be correlated with over all recovery else poor prognoses 
to be considered
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replacement therapy or mechanical ventilation are less likely 
to undergo liver transplantation. Established sepsis/MODS 
precludes transplant and is associated with poor outcome. 
Both deceased and living donor transplants are viable and 
very useful options with very good results [161]. Liver trans-
plant survival has been shown to be above 90% in patients 
with HBV reactivation [162].
Most important aspect in managing this group of sick 
patients is to decide the time frame and an algorithm. If 
the patient is too sick from the beginning and needs early 
LT without waiting for spontaneous recovery, this should 
be decided soon enough. On the other hand, patients who 
are salvageable and need time for recovery should be moni-
tored closely in a time frame before deterioration so that they 
either recover or can undergo LT at an appropriate time. The 
third group is of those who need bridge therapy observed 
while on supportive care and bridging therapy, to define non-
response and emergency LT or for transplant-free survival.
Every ACLF patient at admission needs to be assessed 
for disease severity score, presence of SIRS with or without 
sepsis, HE and number of organ dysfunction/failure. The 
baseline MELD > 28, AARC Score > 10, advanced HE in 
the absence of overt sepsis or multi-organ failure can be 
considered for early LT [3]. In the absence of LT option, 
these patients can be offered early bridge therapies in the 
form of therapeutic plasma exchange and liver dialysis and 
the response could be evaluated by end of first week and the 
possibility of being listed for LT or awaiting spontaneous 
recovery [3, 163]. The maximum recovery from organ fail-
ure, resolution of sepsis and eligibility for LT was observed 
in the first week [3]. The SIRS and/or sepsis and develop-
ment of AKI occur by days 7–15; hence, the interventions 
like prophylactic antibiotics, periodic septic screening with 
the help of biomarkers and avoidance of nephrotixic drugs 
were needed [77].
ACLF is characterized by rapid downhill course 
with extrahepatic organ failure and high short- and 
Disease
severity
score
AUROC Cut off Sensitivity Specificity Positive
predictive
value
Negative
predictive
value
AARC Score 0.804 10.5 71.9 77.5 66.8 77.2
MELD 0.763 30.9 63.5 75.2 63.2 75.4
CLIF
S
OFA 0.750 12.5 48.1 79.2 69.1 61.2
SOFA 0.728 9.5 63.8 69.5 62.2 70.9
APACHE II 0.692 15.5 57.9 68.5 56.8 69.8
CTP 0.657 11.5 68.5 55 50.4 74.9
AARC Score vs. CLIF-C 
0.80(0.75-0.85) vs. 0.75(0.69-0.80),  
p <0.001 
AARC vs. SOFA 
0.80(0.75-0.85) vs. 0.72(0.66-0.78),  
p <0.001 
AARC Score vs. MELD 
0.80(0.75-0.85) vs. 0.76(0.70-0.81),  
p <0.001 
AARC Score vs. APACHE 
0.80(0.75-0.85) vs. 0.69(0.63-0.72),  
p <0.001 
Fig. 5  Comparison of AARC score against other disease severity score
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medium-term mortality ranging from 34 to 51% [1]. 
Although many prediction models of early transplantation 
listing exist, none reliably predicts chances of reversibility 
of ACLF. A recent study showed that the ACLF patients 
develop SIRS and sepsis within 7 days of hospitalization 
[77]. Lin et al. [164] and Pamecha et al. [165] proposed 
serial assessment of these groups of patients in the first 
week of hospitalization for prioritization for liver trans-
plantation. However, being sick, often critically ill and 
admitted to ICUs, rapid progression of liver failure and 
onset of multi-organ failure, transplantation was feasible 
in ~ 25% of patients [165]. Recently, a study showed that 
the LT waiting list mortality in ACLF patients is around 
67% and is predominantly due to sepsis, respiratory failure 
with mechanical ventilation, high vasopressor requirement 
and need of RRT [165]. Though objective criteria were 
not used to define eligibility for LT, patient characteristics 
that were reported to consider an ACLF patient unfit were 
(1) sepsis with 2 or more organ failures or uncontrolled 
sepsis [166], (2) advanced azotemia, i.e., serum creati-
nine > 4 mg/dl or increase in creatinine by 300% from 
baseline or the need of Renal Replacement of therapy 
[167], (3) Respiratory failure [severe ARDS defined by a 
P/F ratio < 150] or HE requiring ventilator support > 72 h 
[168] (4) 4 or more organ failures anytime, (5) active gas-
trointestinal bleeding, and/or (6) hemodynamic instability 
requiring > 3 mg/h noradrenaline [169].
On the other hand, in the absence of liver transplanta-
tion, the outcome is dismal. In fact, liver transplant is poten-
tially the only curative treatment option with good outcome, 
irrespective of etiology in this cohort. An analysis of 1021 
patients from AARC cohort suggested MELD or MELD 
with HE is a good prediction model for making decision 
for LT. A patient with MELD > 27 needs listing, a score of 
30 or above with presence of encephalopathy or new onset 
HE, bilirubin of > 22 mg/dl with INR > 2.5 and grade III-IV 
HE is associated with 80% mortality within 28 days and 
persistence of the same till day 4 is associated with mortal-
ity close to 100%. Hence, these patients need emergent LT 
either at baseline or upon no improvement within day 4–7 of 
hospitalization [163]. So first week of presentation in ACLF 
is crucial [77, 170]. This concept is supported by a window 
of 1 to 2 weeks, i.e., being sick and with no improvement by 
supportive care [171].
Disease severity scores such as MELD have been con-
sidered to determine organ allocation. This disease severity 
score has not taken into consideration of cerebral, circula-
tory and respiratory failure and does not offer any prior-
ity despite being sick [172, 173]. The recently published 
dynamic AARC model consisting of bilirubin, creatinine, 
INR, grade of hepatic encephalopathy and plasma lactate is 
a reliable model to predict the outcome at each time point, 
hence, the need of LT can be considered for prioritizing 
LT but further studies needed on this [3]. Emergency LT, 
promotion of live donor transplant and allocation priority 
in deceased donor setting needs consensus and further large 
size studies [77, 163, 170–176].
Sometimes, patients with ACLF have rapidly worsening 
liver and renal functions, needing quick decisions based on 
renal dysfunction. There is paucity of data on simultaneous 
liver and kidney transplant in this subset of ACLF patients 
[112].
Recommendations
 7.2.  Liver transplantation.
 7.2.1.  No validated criteria and scoring system for early 
and correct identification of patients with ACLF 
who would benefit from early liver transplanta-
tion [2, A].
 7.2.2.  LT should be offered early in the course of 
ACLF. When indicated, early liver transplanta-
tion avoids complications of sepsis and multi-
organ failure [1, B].
 7.2.3.  SIRS, sepsis, HE, liver failure, extrahepatic organ 
dysfunction/organ failure are important prognostic 
factors [2, A].
 7.2.4.  Organ failure per se should not be a contraindi-
cation for liver transplantation, except if cardiac 
or pulmonary support is needed or there is rapidly 
progressive organ failure at day 4 or 7 [2, C].
 7.2.5.  APASL AARC model seems to be better in patient 
selection for liver transplantation as it enrolls 
patients early enough, before organ failure. How-
ever, the AARC score needs to be validated in large 
and varied populations and also its capability to 
predict post LT outcome [2, B].
 7.2.6.  Patients with HBV reactivation with intermedi-
ate MELD should be assessed for early transplant 
if cirrhosis, bilirubin > 10 mg/dL, PT < 40% and 
platelet < 100 ×  109/L [2, C].
 7.2.7.  Steroid ineligible patients with severe alcoholic 
hepatitis should be listed on priority for liver trans-
plant. Selective use of liver transplantation can be 
lifesaving for medically refractory alcoholic hepa-
titis [1, A].
 7.2.8.  Liver transplantation should be reserved for severe 
alcoholic hepatitis patients with low risk of recidi-
vism as assessed by a formal psychosocial evalu-
ation [1, A].
 7.2.9.  Transplant evaluation can be started based on liver 
specific dynamic scores by the end of first week of 
medical treatment or earlier [2, B].
 7.2.10.  Allocation of cadaveric livers should depend on 
maturity of cadaveric program in the country [2, 
C].
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 7.2.11.  Patients with advanced ACLF also have good out-
come after LT [1, A].
Liver dialysis and emerging therapies in ACLF
The hepatocellular injury in ACLF is driven to a large extent 
by a “cytokine burst”, with elevated levels of multitude of 
cytokines, small molecular weight toxins, and vasoactive 
substances which are known to accumulate secondary to the 
failing liver [122]. There is an additional challenge of the 
injury due to endotoxin and metabolites released from gut 
bacteria. These toxins not only potentiate the hepatic injury 
but also deprive the liver of an environment, which is con-
ducive for regeneration. The released toxins are responsible 
for the systemic inflammation, loss of adaptive and innate 
immunity and cause vital organ dysfunction, which affects 
all the major organs [174].
Extracorporeal liver support therapies are used to bridge 
the liver until recovery or liver transplantation in patients 
with ALF and ACLF. Various randomized controlled tri-
als in patients with ACLF have shown improvement in HE, 
hepatorenal syndrome, circulatory dysfunction and immune 
dysfunction without improvement in transplant-free survival 
[175–182]. In the most recent meta-analysis and systematic 
review, no benefit of MARS treatment in reducing mor-
tality as compared to SMT was noted [182]. Even though 
both these meta-analysis have the limitations of enrolling a 
heterogenous group of patients. However, contrary results 
were shown by systematic review by Kjaergard et al. where 
it was seen that ALS reduced mortality by 33% in patients 
with ACLF as compared to SMT [183, 184]. More recently, 
studies have shown that ALS could be an effective form of 
bridging therapy in patients with ACLF with high MELD 
scores awaiting liver transplantation and many believe that 
it is a futile exercise in the absence of liver transplant [185, 
186]. These results have been substantiated by the recently 
published two large European randomized multicentric 
controlled trials, i.e., HELIOS (for Prometheus) [177] and 
RELIEF trial (for MARS) [176] which failed to show any 
benefit with these modalities on short-term transplant-free 
survival which was the primary end point of these studies. 
The foremost reason for no demonstrable survival benefit 
with the currently available artificial liver support systems 
is the functional incompetence as most of these provide only 
the detoxification function of the entire armamentarium of 
liver functions and thus incorporation of synthetic function 
by living hepatocytes, i.e., the “bioartificial liver” or thera-
pies to potentiate hepatic regeneration look more realistic. 
The other major challenge that remains is to decide the tim-
ing of therapy so as to derive maximal therapeutic benefit, 
i.e., whether to consider it before or after the onset of sepsis 
because by the time multi-organ failure is manifest, the bene-
fits of intervention with these devices are not to be expected.
In a large proportion of patients with ACLF, however, 
liver transplant is not feasible, due to lack of an organ, a 
donor, severity of the illness or other social challenges. 
There are few alternatives at present to liver transplant. 
There have been promising results of the use of growth 
factors in such patients. Garg et al. [28] have shown that 
granulocyte colony-stimulating factor (GCSF) can help in 
hepatic regeneration by mobilizing bone marrow-derived 
CD34 + cells. In addition, it significantly reduced the devel-
opment of sepsis and subsequent multi-organ failure. These 
data were substantiated in another study from the East in 
patients with HBV-related ACLF [187–194].
However, despite the encouraging results and two rand-
omized controlled clinical trials, it was felt that the use of 
these agents should be undertaken only under protocols and 
more data are required before recommending routine use of 
these agents.
Recommendations
 7.3.1.  Plasma exchange appears to be a promising and 
effective bridging therapy in patients with ACLF 
to liver transplant or spontaneous regeneration [1, 
C]
 7.3.2.  Plasma exchange can be safely undertaken in 
patients with ACLF in specialized liver units [2, B].
 7.3.3.  Plasmapheresis may be considered as a specific 
therapy for patients with Wilson’s disease and 
patients with severe flare of autoimmune liver dis-
ease (deemed unsuitable for steroids) [2, B].
 7.3.4.  Combination of PE with therapies to potentiate 
liver regeneration should be evaluated in patients 
with ACLF [2, C].
Acute‑on‑chronic liver failure in children
An extensive PubMed search using keywords ‘Acute-on-
chronic liver failure in children; ACLF in children; Pediatric 
acute-on-chronic liver failure; Pediatric ACLF’, returned 
only 5 studies, from 3 Indian centers [195–199]. The data 
on pediatric ACLF are limited and largely retrospective. 
Pediatric ACLF, although less commonly described in the 
literature, is not uncommon with a recent study demonstrat-
ing that around 14% of all CLD presented as ACLF [195]. 
ACLF was the first manifestation of a previously unknown 
underlying CLD in 75–100% cases as reported in some stud-
ies [196–198]. The combined data from the 3 centers showed 
that Wilson disease (41.2 – 45.7%) followed by autoimmune 
liver disease (17.6–41.9%) are the commonest CLD present-
ing as ACLF followed by cryptogenic cirrhosis (3.2–41.2%) 
[195–199]. The acute precipitating event was a hepatotropic 
viral insult (37–94.1%) in most. Flare of autoimmune liver 
disease (9.6–17%) and Wilson disease (0–27%), defined as 
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ACLF in the absence of a recognizable acute event were also 
reported [196, 197], although the definition used is not estab-
lished. In a study, no acute hepatic event was found in 29% of 
patients, a proportion of which could have been flare of Wil-
son disease [198]. As cholangitis is not currently accepted as 
parenchymal insult, which happens to be the most important 
event leading to decompensation in biliary atresia, the experts 
decided to exclude biliary atresia from ACLF definition.
Only 8.7% of the pediatric ACLF cohorts were ≤ 3 years. 
Metabolic liver diseases (MLD) account for majority of 
CLD in this age group. On analysis of MLD data, it was 
found that only 3/63 (4.8%) could fulfill the definition of 
ACLF but were labeled as ALF as there is some overlap in 
the 2 definitions [1, 199]. Children with MLD also failed 
to fulfill the definition of ACLF as a proportion of them 
either had longer jaundice to HE/ascites interval [200] or 
had anicteric liver failure. The common acute precipitating 
events of pediatric ACLF present less often before 5 years 
of age: acute hepatitis A in 15.7% (personal communica-
tion ILBS data) & drug hepatotoxicity: 27.8% [201].
Do we need a modified definition of pediatric ACLF?
There is no separate definition of pediatric ACLF. The 
major issues with the current definition in children are: (1) 
clinical identification of hepatic encephalopathy is often 
difficult and/or delayed specially those below 3 years of 
age, (2) clinical ascites may be difficult to identify espe-
cially in younger children with organomegaly, (3) some 
pediatric liver disease may present with liver failure 
without jaundice. The current ACLF definition requires 
jaundice to be followed by clinical ascites or HE within 
4 weeks [1]. A delayed clinical identification or non-
identification of HE/ascites will lead to the patient either 
being identified beyond the period of golden therapeutic 
window or not even diagnosed as ACLF. To circumvent 
the issue of difficult identification of HE, pediatric acute 
liver failure study group has defined acute liver failure 
as an INR greater than 2 regardless of the presence or 
absence of clinical HE [199]. Pediatric ACLF cohort at 
Institute of Liver and Biliary Sciences (ILBS) was evalu-
ated to determine if the cutoff INR for defining ACLF can 
be increased to 2 regardless of the presence or absence of 
clinical HE. In the presence of HE, poor outcome was seen 
in 42.9% and 56.6% of those with INR between 1.5 and 2 
(18/90) and those with INR ≥ 2 (74/90), respectively. As 
identification of HE is important but clinical identification 
often difficult, ammonia which has good correlation with 
HE [202] was evaluated as a surrogate marker. Ammonia 
performed poorly for diagnosis of HE with AUROC of 
0.642 and an ammonia level more than 150 ug/dl diag-
nosed HE with 61.3% sensitivity and 70% specificity. EEG 
is another surrogate but is difficult to perform, not easily 
available and has not been standardized in children [203]. 
In the absence of a good surrogate, the experts agreed that 
clinical HE should continue to remain part of the defini-
tion. West Haven scale is used in older children, whereas 
modified HE assessment scale can be used for identifying 
and grading HE in children up to 3 years of age [199]. 
Detection of clinical ascites is difficult or delays diagnosis. 
Radiological ascites (mild to massive) from the ultrasound 
report and clinical ascites from the discharge summaries 
were compared in 127 children aged up to 3 years with 
CLD. The sensitivity of clinical examination to detect 
ascites was 71% with 29% being missed or identified later 
when the ascites increased further. Hence, the experts 
agreed to replace clinical ascites with clinical/radiologi-
cal ascites in children.
Outcome and prognostication in pediatric ACLF
Theoretically, pediatric ACLF should have a better outcome 
than adults as the 2 commonest CLD, i.e., Wilson disease 
and autoimmune liver disease presenting as pediatric ACLF 
have specific medical therapy, better hepatic reserve (due 
to shorter duration of illness) and lesser incidence of co-
morbidities. Outcome has been defined at different time 
points in the published pediatric literature [195–204]. Wil-
son disease and cryptogenic cirrhosis have poor prognosis 
with 48.8% and 30% survival, respectively. Those with 
acute HEV (50%), DILI (37.5%) and flare of Wilson dis-
ease (37.5%) have low survival. Half of the pediatric ACLF 
have one or more organ failure, with the commonest being 
cerebral and renal. Presence of ≥ 3 organ failures was asso-
ciated with poor outcome. Outcome was poor in those with 
AKI and grade 3–4 HE. The presence of AKI increases the 
likelihood of death several folds [204]. Among the prog-
nostic models evaluated in ACLF, APACHE-III, SOFA and 
CLIF SOFA score have been described in children [196, 
197]. AARC score was recently shown to have excellent 
prognostic value in adult ACLF cohort [3]. Serum creati-
nine (SCr) value included in AARC score is unreliable as 
children have lower SCr, which is further accentuated due 
to malnutrition, sarcopenia and decreased endogenous pro-
duction. A pediatric modification of AARC score was made 
replacing the absolute SCr with grades of AKI [204]. Both 
the AARC score (AUROC 0.945) and its pediatric modifica-
tion (AUROC 0.951) were superior to the other prognostic 
scores in pediatric ACLF cohort. A cutoff score of 11 or 
more identified poor outcome with 87.5% sensitivity and 
90.6% specificity. Poor outcome group showed a rise, while 
the good outcome group showed decline in AARC-ACLF 
score at day 4 (∆AARC-ACLF: Poor outcome: 1 ± 1.1 vs. 
Good outcome: − 0.6 ± 0.9, p < 0.0005) [204].
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The proposal for a definition of ACLF in children by the 
APASL is the first such attempt to address the issue of ACLF 
in children. Hope this will be enriched by further large and 
multicentric studies in future.
Recommendations
 8.0.  Acute-on-chronic liver failure in children.
 8.1.  Pediatric ACLF is not uncommon (1, B).
 8.2.  The most common underlying liver diseases presenting 
as ACLF in children are Wilson disease and autoim-
mune liver disease (1, B).
 8.3.  The most common acute precipitating events are viral 
(HAV, HEV, HBV) hepatitis and flare of underlying 
disease/hepatotoxic drugs (1, B).
 8.4.  Standardized definitions of disease flare, as a precipi-
tating event need to be further updated (2, C).
 8.5.  The existing definition of ACLF can be used to diag-
nose ACLF in children. However, there is an urgent 
need to generate more multicentric data from prospec-
tive studies.
 8.6.  Clinical diagnosis of hepatic encephalopathy, though 
difficult, is important for diagnosis/prognosis of pediat-
ric ACLF. For diagnosis of HE in older children, West 
Haven scale can be used. For children less than 3 years, 
modified HE assessment scale can be used (2, C).
 8.7.  Clinical and/or radiological ascites can be used for 
defining ACLF in children (2, B).
 8.8.  Short-term (28-day) outcome is poor in approximately 
33% of pediatric ACLF subjects (2, B).
 8.9.  One or more extrahepatic organ failures are seen in 
around half of children with ACLF (1, B).
 8.10.  Acute kidney injury and grade 3-4 HE are most com-
mon extrahepatic organ failures in pediatric ACLF.
 8.11.  Half the cases of ACLF at presentation have AKI. The 
presence of AKI increases the risk of poor outcome by 
several folds (2, B).
 8.12.  AARC-ACLF model is an easy, bedside, dynamic 
prognostic model for pediatric ACLF (B, 2).
 8.13.  A score more than or equal to 11 needs urgent listing 
and evaluation for liver transplant (2, B).
 8.14.  Pediatric modification of these scores may be useful 
(2, C).
Conclusions
In summary, the field of ACLF has moved very rapidly in the 
past 5 years. The availability of large volume of published data 
from the East and the West has allowed reassessing the initial 
definitions. The need for having a well-defined homogenous 
population of patients, with wellcharacterized acute and chronic 
insult and which would reflect the term acute-on-chronic liver 
failure, is at the core. Attempts to abrogate, ameliorate or 
reverse the ongoing injury would allow return of hepatic syn-
thetic functions and reversal of the liver damage. Early predic-
tors of mortality and non-reversibility of the condition would 
pave way to offer priority liver transplantation to such patients. 
An attempt to converge the thoughts from the East and West is 
possibly the only way forward to achieve more scientific and 
timely interventions for such seriously sick patients.
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